Document:

exv10w1

Exhibit
10.1

AMENDED AND RESTATED SUPPLY AND DEVELOPMENT AGREEMENT

     This Amended and Restated Supply and Development Agreement (“Agreement”) is made as of
the 28th day of January, 2011 (“Effective Date”), by and between LifeCell Corporation, a
Delaware corporation (“LifeCell”), and Wright Medical Technology Inc., a Delaware
corporation (“Distributor”). This Agreement replaces and supersedes in its entirety the
Supply and Development Agreement, as amended, dated April 1, 2002, by and between LifeCell and
Distributor. Capitalized terms used in this Agreement have the meanings given to them in Section
18.1 or elsewhere in this Agreement.

Witnesseth:

     WHEREAS, LifeCell is engaged in the business of, among other things, processing tissue using
its proprietary AlloDerm® process and marketing and selling tissue processing services to health
care providers;

     WHEREAS, Distributor is engaged in the business of, among other things, distributing products
and services to health care providers;

     WHEREAS, the parties desire that LifeCell engage Distributor to distribute Products to
Customers and that Distributor distribute Products to Customers on the terms and conditions
hereinafter set forth;

     NOW, THEREFORE, in consideration of the foregoing, the mutual covenants contained herein and
other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
and intending to be legally bound, the parties hereto hereby agree as follows:

1. Distribution of the Products.

     1.1 Appointment. LifeCell hereby appoints Distributor as its exclusive authorized distributor of the
Products to Customers in the Sales Territory for use within the Sales Territory in accordance with
the provisions of this Agreement. Distributor hereby accepts such appointment and agrees to use
all commercially reasonable efforts to develop and exploit the market and to solicit sales and
obtain orders for the purchase of Products for which its appointment as distributor is effective
and for use within the jurisdiction in the Sales Territory for which such appointment then is
effective. Distributor acknowledges that nothing contained in this Agreement grants Distributor
the exclusive, non-exclusive, or any other right whatsoever to sell or distribute Products to
persons in the Sales Territory that are not Customers and Distributor hereby agrees that it will
sell Products to Customers only in the Sales Territory, which Customers, to the best knowledge of
Distributor, after due inquiry, will use Products sold to them on or before June 30, 2011, only in
the Sales Territory for orthopedic applications and podiatric wound applications and Products sold
to them after June 30, 2011, only in the Sales Territory for orthopedic applications. LifeCell
hereby expressly retains all distribution and other rights in connection with the Products and
Processed Tissue not specifically granted to Distributor under this Agreement.

2. Distributor’s Duties.

     2.1 Distributor’s Duties. Distributor’s duties hereunder shall include:

          (a) promoting and selling the Products to Customers in the Sales Territory through
Distributor’s trained field sales representatives;

          (b) regularly and diligently soliciting Product orders from present and potential Customers
within the Sales Territory for use within the Sales Territory;

 

 

          (c) supporting, developing, administering, monitoring and participating in Market Development
Programs in accordance with Section 5;

          (d) consulting with and furnishing information to LifeCell concerning Customers’ requirements
and other matters that may affect Product sales in the Sales Territory;

          (e) not giving any warranties in favor of Customers or proposed Customers beyond those
contained in Section 4.9 hereof;

          (f) being responsible for reporting to LifeCell all information in Distributor’s possession or
of which Distributor is aware, upon reasonable request by LifeCell to enable LifeCell to ensure
that the Products meet all applicable laws, rules and regulations relating to health, safety,
labeling and the like;

          (g) refraining from any act or practice that (i) reasonably might tend to diminish or inhibit
Product sales or in any way adversely reflect upon LifeCell, provided, however, except as limited
by subsection (i) below, nothing contained herein shall restrict Distributor from developing or
otherwise acquiring rights to or selling (1) synthetic derived graft containment products, or (2)
xenograft tissue products, provided, however, that if xenograft tissue products exceed [***]% of
Distributor’s sales of graft containment products, Lifecell at its option may change the Agreement
to non-exclusive, and if xenograft tissue products exceed [***]% of Distributor’s sales of graft
containment products, Lifecell at its option may terminate the Agreement; or (ii) constitutes a
violation of applicable law;

          (h) refraining from promoting, soliciting or otherwise participating in the sale of human
derived soft tissue graft containment products that directly compete with the Products, in North
America during the Term, and solely if this Agreement is terminated by LifeCell due to a material
and intentional breach by Distributor hereof which is not remedied within applicable cure periods
for [***] after such termination of this Agreement (and the foregoing shall survive such
termination of this Agreement for a period of [***], if applicable); provided, however, that
Distributor may develop a human-derived dermal product offering (which may not be commercialized
during the Term), subject to Distributor providing LifeCell with written notice upon initiation of
human clinical studies and trials to obtain clinical validation of the human-derived dermal
product;

          (i) subsequent to June 30, 2011, refraining from promoting, soliciting or otherwise
participating in the sale of human and non-human derived soft tissue graft containment products in
the field of wound care treatment, including, without limitation, the care and treatment of acute,
surgical, and chronic wounds, such as, by non-limiting example, diabetic foot ulcers, venous leg
ulcers, and pressure ulcers, except that Distributor may promote, solicit or otherwise participate
in the sale of current or future products based on Distributor’s [***] currently marketed under the name “Biotape” (the “WMT Porcine Platform”) to
the hospital market, provided that Distributor will not, and will not permit, authorize, or license
any third party to, begin commercial sales of any new products based on the WMT Porcine Platform
(i.e. products not sold by Distributor as of the Effective Date) that are specifically indicated
for wound care applications to the hospital market prior to the second anniversary of the Effective
Date (the “Exclusion Period”). For the avoidance of doubt, the hospital market shall not include
the post acute wound care market, including, without limitation, wound care facilities, outpatient
facilities, or ambulatory surgical centers.

 

			
	[***]	 	Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

-2-

 

          (j) refraining from changing Product or Processed Tissue labels or containers, repackaging the
Products or Processed Tissue, or otherwise presenting or marketing the Products in competition with
or as similar substitute items for other products of LifeCell sold in the Sales Territory;

          (k) furnishing to LifeCell for prior review and approval copies of all proposed Marketing
Materials in accordance with Section 9.5 and refraining from or discontinuing the use of any
Marketing Materials which in the reasonable opinion of LifeCell are false or misleading or may
subject LifeCell to liability;

          (l) providing to LifeCell Updated Product Forecasts during the Term in accordance with Section
4.8;

          (m) providing to LifeCell, on or before the fifteenth day of each month, a report of sales of
the Products in the immediately preceding month in the United States and, if applicable, on or
before the fifteenth day of each month immediately following each Sales Quarter, a report of sales
of Products in the immediately preceding Sales Quarter to each country other than the United States
in the Sales Territory, with each report listing the total dollar amount of sales and total number
of Units.

          (n) refraining from (i) acting in any manner that could expose LifeCell to any liability
beyond such exposure as is inherent in connection with introducing a product, such as the Products,
into the market and Sales Territory as is contemplated by this Agreement and (ii) pledging or
purporting to pledge LifeCell’s credit;

          (o) informing LifeCell of any infringements of its patents, trademarks and other proprietary
rights known to Distributor and using commercially reasonable efforts to assist LifeCell in the
safeguarding of such legal rights at LifeCell’s sole expense;

          (p) not disputing the right of LifeCell to its trademarks;

          (q) not marketing the Products (i) for sale, delivery or use outside the Sales Territory,
unless otherwise agreed in writing in advance with LifeCell, (ii) for sale inside the Sales
Territory if, to Distributor’s knowledge, after reasonable inquiry, the Products are ultimately
destined for delivery or use outside the Sales Territory, unless otherwise agreed in writing in
advance by LifeCell, or (iii) for sale, delivery or use, inside or outside the Sales Territory, to
persons that are not Customers, unless otherwise agreed in writing in advance by LifeCell;

          (r) not marketing, promoting, soliciting, or, directly or indirectly, knowingly selling the
Product or allowing the Product to be sold for use in any application other than orthopedic
applications, other than during the period commencing on the Effective Date through June 30, 2011
(the “Wind Down Period”), when Distributor may market and sell the Product for orthopedic
applications, on an exclusive basis, and podiatric wound care applications, on a non-exclusive
basis;

          (s) immediately upon expiration of the Wind Down Period, returning to LifeCell all Products
intended to be sold for podiatric wound care applications (i.e. unsold [***] Sheet Products and all
Micronized Products), for which Distributor shall receive a credit in the amount equal to [***] paid for such products, but not to exceed [***] Distributor’s average
monthly unit volume sales of such products over the [***] period immediately preceding the
repurchase date, to be applied against future Product purchases;

 

			
	[***]	 	Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

-3-

 

          (t) complying, at its sole expense and prior to any sale of Products in the Sales Territory,
with all laws, rules and regulations applicable to the performance of its duties under this
Agreement and to the operation of this Agreement, including the filing of all documents and
obtaining of all permits, authorizations and the like required by the laws of all the jurisdictions
in the Sales Territory, and providing to LifeCell promptly upon LifeCell’s request, reasonable
evidence of such compliance;

          (u) securing and maintaining insurance, including product liability insurance, of at least
$[***] in accordance with Section 2.2;

          (v) paying any and all expenses of and incidental to the distributorship obligations hereunder
incurred by the Distributor, including without limitation, costs and expenses associated with
Marketing Materials; salaries, commissions and benefits of Distributor’s employees and agents, as
applicable; taxes, imposts, charges and assessments levied by any appropriate governmental or
jurisdictional authority in connection with the purchase and sale of Products in the Sales
Territory; and

          (w) supporting and participating in Clinical Development Programs in accordance with Section
5.

     2.2 Insurance. Distributor shall maintain, during the Term, Comprehensive or Commercial General
Liability insurance, which shall include without limitation, broad form liability and products
liability coverage with minimum limits of [***] per occurrence/aggregate. Distributor shall
furnish LifeCell with such insurance certificates prior to the delivery of Products hereunder and
during the Term as LifeCell may require.

3. LifeCell’s Duties.

     3.1 LifeCell’s Duties. LifeCell’s duties hereunder shall include:

          (a) providing Distributor with specimens of its existing promotional materials and marketing
brochures and copies of relevant documents either in its possession or commercially reasonably
obtainable by LifeCell relating to regulatory approvals;

          (b) providing Distributor such reasonable assistance, as shall be determined mutually by
LifeCell and Distributor, to be appropriate to support Distributor’s promotional and advertising
activities within the Sales Territory, including LifeCell sending one LifeCell employee or
consultant knowledgeable about the Products to no more than three (3) significant industry trade
shows each Sales Year and to conduct two (2) training sessions concerning the Products each Sales
Year;

          (c) referring to Distributor all orders and inquiries from Customers relating to the sale of
Products within the Sales Territory; provided, however, that LifeCell shall not have the duty to
refer orders and inquiries relating to podiatric wound care applications during the Wind Down
Period;

          (d) supporting and participating in Clinical Development Programs in accordance with Section
5;

          (e) including Distributor as an additional insured on LifeCell’s product liability insurance
policy;

 

			
	[***]	 	Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

-4-

 

          (f) securing and maintaining product liability insurance of at least $[***];

          (g) supplying Distributor with Product in accordance with the Delivery Schedule. Furthermore,
Lifecell agrees that delivery of Product to Distributor is not, and will not be incumbered by any
contract, or other agreement in which priority or preferential delivery, obligations are offered to
any other party, distributor or dealer of Lifecell products or services;

          (h) maintaining the Intellectual Property related to the Product;

          (i) limiting the use of the Product for orthopedic applications exclusively to Distributor,
and limiting the use of the Product to Distributor for podiatric wound applications, on a
non-exclusive basis, during the Wind Down Period. Without limiting the generality of the
foregoing, LifeCell will not, at any time during the term of this Agreement, directly or indirectly
(i) knowingly sell or distribute the Product, or permit the Product to be sold or distributed, for
use in any orthopedic application, (ii) appoint, engage or authorize any other person or entity to
act as a seller or distributor of the Product for use in any orthopedic application or as its
representative or agent in connection with the sale or distribution of any Products for use in any
orthopedic application, or (iii) pay any commissions or other compensation to any person or entity
for or in connection with the sale or distribution of the Product for use in any orthopedic
application;

          (j) refraining from (i) acting in any manner that could expose Distributor to any liability
beyond such exposure as is inherent in connection with introducing a product, such as the Products,
into the market and Sales Territory as is contemplated by this Agreement and (ii) pledging or
purporting to pledge Distributor’s credit;

          (k) not disputing the right of Distributor to its trademarks;

          (l) granting Distributor exclusive distribution rights in the orthopedic field and on the
terms and conditions set forth in this Agreement to any next generation human tissue products
commercialized by LifeCell that the parties mutually agree are both commercially viable and
clinically appropriate for orthopedic applications (which agreement shall not be unreasonably
withheld or delayed by LifeCell). No later than [***] of Distributor’s commercialization of a next generation human tissue product, the parties shall
determine the increase in annual Product sales reasonably attributable to such next generation
human tissue product during the previous [***] (net of any cannibalization of prior
generation Product sales), and make a [***] increase in the Minimum Annual Payment [***] in an amount proportionate to such net increase. Thereafter, no later
than February 28 of each calendar year during the Term, the parties shall analyze and discuss
whether a further increase in the Minimum Annual Payment is appropriate based on increases in
annual Product sales achieved during the prior periods which are attributable to next generation
human tissue products. For purposes of this Section, a “next generation human tissue product”
shall mean a new acellular, [***], human dermal sheet product offering commercialized by LifeCell
(other than an Enhanced Sheet Product). LifeCell will provide Distributor with written notice of
any next generation human tissue product that is both commercially viable and clinically
appropriate for orthopedic applications prior to commercializing any such application outside the
orthopedic field of use, and will cooperate with Distributor in the evaluation, development and
commercialization of such applications in the orthopedic market. Any such next generation human
tissue product shall be added to the definition of “Product” hereunder upon the granting to
Distributor of exclusive distribution rights in the

 

			
	[***]	 	Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

-5-

 

orthopedic field with respect thereto pursuant to the provisions of this paragraph. All product
development and implementation costs associated with the
commercialization of the next genertion
human tissue product in the orthopedic field shall be borne by Distributor, including, without
limitation, labeling costs, SKU sizes, and thickness preparation. Notwithstanding the foregoing,
any future products resulting from changes to enhance, improve, or modify the Sheet Products, for
the orthopedic field, that combine the Sheet Products with [***], or other
[***] are hereafter referred to as “Enhanced Sheet Products” and
shall not be considered next generation human tissue products hereunder. Distributor has not been
granted any rights with respect to any Enhanced Sheet Products under this Agreement, but LifeCell
may elect under separate terms and conditions to enter into an agreement with Distributor to
develop, commercialize or use one or more Enhanced Sheet Products. In no event shall LifeCell
enter into any agreement with a third party to commercialize any Enhanced Sheet Product without
first providing Distributor the opportunity to accept or refuse such an agreement offered on equal
terms and conditions, which acceptance or refusal shall be provided in writing [***] after
written notice is sent from LifeCell describing in reasonable detail the subject Enhanced Sheet
Product and the terms and conditions of the proposed agreement with such third party with respect
to the commercialization thereof. LifeCell will promptly provide the Distributor with any and all
data and information relating to such Enhanced Sheet Product that Distributor may reasonably
request to facilitate its assessment of the viability of such product for orthopedic applications.
Failure by Distributor to provide written acceptance [***] shall be deemed a
rejection of the right to commercialize the Enhanced Sheet Product;

          (m) cooperating with Distributor on the evaluation and potential development of any specific
project ideas, new product configurations, or potential additional indications in the orthopedic
field that are communicated to LifeCell by Distributor; provided the business case for each of
foregoing is reasonably acceptable to both parties (which acceptance shall not be unreasonably
withheld or delayed by LifeCell). All product development and implementation costs associated with
the commercialization of the foregoing in the orthopedic field shall be borne by Distributor,
including, without limitation, labeling costs, SKU sizes, and thickness preparation. Further, no
later than [***] of Distributor’s commercialization of a new project
idea, configuration or indication in the orthopedic field, the parties shall determine the increase
in annual Product sales reasonably attributable to such project idea, configuration and/or
indication during the previous [***] (net of any cannibalization of prior generation
Product sales), and make a [***] increase the Minimum Annual Payment [***] in an amount proportionate to such net increase. Thereafter, no later than February 28 of
each calendar year during the Term, the parties shall analyze and discuss whether a further
increase in the Minimum Annual Payment is appropriate based on increases in annual Product sales
achieved during the prior periods which are attributable to such project idea, configuration and/or
indication; and

          (n) within forty-five (45) days following the end of the Wind Down Period, repurchasing
Distributor’s remaining inventory of [***] Sheet Product and Micronized Product from Distributor at
a price equal to [***], not to exceed [***] Distributor’s average monthly unit volume sales of such products [***] period
immediately preceding the repurchase date.

 

			
	[***]	 	Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

-6-

 

4. Terms and Conditions of Sale.

     4.1 Minimum Annual Product Sales.

          (a) During the Term, Distributor is required to achieve Minimum Annual Product Sales. The
total United States dollar-value amount of sales of all Products to Customers that are recognized
by Distributor as revenue pursuant to United States Generally Accepted Accounting Principles during
any given calendar year period, beginning with the year ending December 31, 2004, are hereafter
referred to, respectively, as “Annual Product Sales”. Minimum Annual Product Sales for the
calendar years ending December 31, 2004 and 2005 are $[***] and $[***] respectively, per year.
Within thirty (30) days after completion of the calendar year ending December 31, 2006, and within
thirty (30) days following the completion of each calendar year through 2010, Distributor shall
calculate the compound annual growth rate of its Annual Product Sales for the most
recently-completed two year period (hereafter referred to as the “Two Year CAGR”) pursuant to the
following formula:

Two Year CAGR = (v(Ac/ Ac-2) ) — 1

     Wherein; Ac = Annual Product Sales during the most recently completed calendar
year;

     Ac-2 = Annual Product Sales during the calendar year two years prior to the most
recently-completed calendar year, and;

     √ = the square root of a number;

     As an example, if Ac equals $1,000,000 and Ac-2 equals $800,000, then
the 2010 Two Year CAGR computes to equal .1180, or 11.80%. As a further example, if Ac
equals $1,000,000 and Ac-2 equals $1,200,000, then the Two Year CAGR, equals -.0871, or
negative 8.71%.

     In any calendar year during the period from the calendar year ending December 31, 2006 through
the calendar year ending December 31, 2010, if the Distributor achieves a Two Year CAGR of less
than [***], as determined in accordance with this Section 4.1(a) (the “Pre-2011 Minimum Annual
Product Sales”), the Distributor shall pay to LifeCell an amount equal to the difference between
(i) the Revenue Share Amount that LifeCell would have received pursuant to Section 4.3 if
Distributor had achieved the Pre-2011 Minimum Annual Product Sales, and (ii) the amount actually
earned by LifeCell pursuant to Section 4.3 (the “Pre-2011 Catch-up Amount”). The pre-2011 Catch-up
Amount shall be due and payable by Distributor within thirty (30) days following Distributor’s
determination of the pre-2011 Two Year CAGR pursuant to the second sentence of this Section.

          (b) Beginning in the calendar year ending December 31, 2011, or any calendar year thereafter,
if Distributor’s Annual Product Sales are less than $[***] (the “Minimum Annual Product Sales”),
Distributor shall, within sixty (60) days following the completion of that respective period,
provide LifeCell with a plan for improving Distributor’s sales of Products to Customers. LifeCell
at its sole and absolute discretion, shall thereafter be entitled to change Distributor’s status as
exclusive distributor of Products in the Sales Territory to non-exclusive distributor of Products,
unless Distributor pays to LifeCell, within ninety (90) days following the completion of that
respective period, a “Catch-up Amount” equal to any difference between (x) the Revenue
Share Amount that LifeCell would have received pursuant to Section 4.3 if Distributor had achieved
the Minimum Annual Product Sales for that respective period and (y) the amount actually earned by
LifeCell pursuant to Section 4.3.

 

			
	[***]	 	Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

-7-

 

          (c) In the event that Distributor In the event that Distributor achieves a Two Year CAGR of
less than negative [***] for any period consisting of two consecutive calendar years during the
Term prior to December 31, 2010, as determined in accordance with Section 4.1(a), or Annual Product
Sales of less than $[***] in any calendar year during the Term after December 31, 2010 (the
“Terminable Minimum Annual Product Sales”) Distributor shall, within sixty (60) days following the
completion of that respective period, provide LifeCell with a plan for improving Distributor’s
sales of Products to Customers. LifeCell at its sole and absolute discretion, shall thereafter be
entitled to terminate this agreement, unless Distributor pays to LifeCell, within ninety (90) days
following the completion of that respective period, a “Termination Catch-up Amount” equal
to any difference between (x) the Revenue Share Amount that LifeCell would have received pursuant
to Section 4.3 if Distributor had achieved the Terminable Minimum Annual Product Sales for that
respective period and (y) the amount actually earned by LifeCell pursuant to Section 4.3 plus any
previous Catch-up Amounts and Termination Catch-up Amounts paid during that respective period.

          (d) With respect to any calendar year during the Term, in the event that LifeCell is unable to
furnish Distributor, for any reason, with the Number of Units of each respective Product and Sizes
as established in Updated Product Forecasts pursuant to Section 4.8(a), or should LifeCell, for any
reason including a force majeure event, decline to accept an Updated Product Forecast wherein the
Number of Units of each respective Product and Sizes requested by Distributor falls within the
allowable percentage increase provisions established in Section 4.8(a), for purposes of calculating
the Minimum Annual Product Sales, the Distributor shall be allowed to include in its calculations
of the Minimum Annual Product Sales and Terminable Minimum Annual Product Sales, a sales amount
representative of what would have been derived from the number of units that LifeCell was unable to
furnish. For purposes of that period’s calculation, Distributor will be deemed to have achieved
those Product Sales. Additionally, should LifeCell’s inability to meet Distributor requests for
any of the Products be prolonged for more than twelve (12) months, Distributor shall be deemed to
have achieved the Minimum Annual Product Sales criteria set forth in Section 4.1(b) for the periods
in which the prolonged supply constraint occurred. Except as otherwise provided in Section 4.3,
4.9(b), 4.12 and 7.4, Distributor shall have no right and LifeCell shall have no obligation to
accept returns from Distributor of Products.

          (e) LifeCell, at its expense, shall have the right upon no less than five (5) days advance
written notice to Distributor and no more often than one (1) time per year, to have an independent
consultant chosen by LifeCell, inspect and audit Distributor’s books and records reasonably
necessary or desirable to determine Distributor’s compliance with its obligations under this
Agreement. Such audit shall not be limited to the fiscal year in which the audit is performed.
Any audit performed pursuant to LifeCell’s right to audit shall be at LifeCell’s expense. This
Section 4.1(e) shall survive any expiration or termination of this Agreement for a period of two
years.

     4.2 Transfer Price. LifeCell shall supply Sheet Products to Distributor at the price of [***] per
square centimeter of Product and, until the expiration of the Wind Down Period, LifeCell shall
supply Micronized Products to Distributor at prices consisting of [***] for the current one cubic
centimeter size and [***] for the current two cubic centimeter size (hereinafter such price of the
respective Products is referred to as the “Transfer Price”); provided, however, that in no
event shall LifeCell increase the respective Transfer Prices (i) effective more than once in any
Sales Year and/or (ii) by more than [***] in any Sales Year. LifeCell shall use commercially
reasonable efforts to provide ninety (90) days prior written notice to Distributor of any increase
in Transfer Prices and inform Distributor of such potential increases on or before November 15 of
each Sales Year, LifeCell may increase the Transfer Price by

 

			
	[***]	 	Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

-8-

 

more than [***] in any Sales Year only if the costs associated with processing Processed Tissue
increases by more than [***] in any Sales Year. In such an event LifeCell may increase the
Transfer Price above [***] and up to the increase in costs associated with processing Processed
Tissue. In the event that LifeCell increases Transfer Prices by more than [***]% in any Sales
Year, Distributor may terminate this Agreement upon thirty (30) days written notice to LifeCell by
providing such written notice to LifeCell within sixty (60) days after receiving LifeCell’s
Transfer Price increase notice.

     4.3 Revenue Share Payment. The Distributor shall, with respect to all Product sold to Customers during
a Sales Quarter, pay to LifeCell an amount equal to [***]% of the gross sales price invoiced by
Distributor to the Customers for such Products (“Revenue Share Amount”), less the Transfer
Price previously paid by Distributor to LifeCell for such Products (the net amount of the Revenue
Share Amount less the Transfer Price, hereafter, the “Revenue Share Payment”). In the
event that the Revenue Share Amount for Products sold during a respective Sales Quarter is less
than the Transfer Price of such Products, the Revenue Share Payment for such sold Products shall be
zero, and Distributor shall not be entitled to any credit against other Product Revenue Share
Payments in past or future Sales Quarters. (For example, if Distributor sells Products to
Customers during a Sales Quarter in an amount that totals $100,000.00, and the Transfer Price of
those Product units when purchased from LifeCell was $10,000.00, the Revenue Share Payment to be
paid to LifeCell upon sale of the Product is $[***], calculated as $[***] less the Product Transfer
Price of $10,000.00.) Distributor shall be entitled to a credit for any Revenue Share Payment made
for any unit of Product that is rejected or returned by a Customer.

     4.4 Payment Terms. The Distributor shall (i) pay for the Products purchased hereunder by cash within
forty five (45) days of the later of the date of shipment or the invoice date for such Products and
(ii) pay the applicable Revenue Share Payment for sale of the Product to Customers by cash within
45 days following each month occurring during the Term of this Agreement. Interest at the lesser
of the per annum rate of [***] or the highest interest rate permitted under
applicable law shall accrue, and Distributor shall pay to LifeCell such interest on any amounts
owed to LifeCell for Products purchased and Revenue Share Payments, which amounts have not been
paid to LifeCell within forty five (45) days of the later of the date of shipment or the invoice
date for such Products with respect to payments for Products or within 45 days following the month
in which Revenue Share Payments are earned with respect to Revenue Share Payments. LifeCell, in
its sole discretion, may terminate this Agreement upon 30 days prior written notice of termination
(the “Notice Period”) to Distributor if any invoice (including invoices for interest accrued and
payable under the terms hereof) from LifeCell to Distributor remains unpaid for more than 45 days
from the later of the date of such invoice or the date of the related shipment and Distributor has
not paid such invoice, together with accrued unpaid interest thereon as provided herein, upon
expiration of the Notice Period. Notwithstanding the foregoing or anything to the contrary
contained in this Agreement, in the event that LifeCell provides written notice of non-payment to
Distributor pursuant to this Section 4.4 more than once in any Sales Year, LifeCell may
immediately, without the requirement of a Notice Period, either (i) change Distributor’s status as
exclusive distributor of Products in the Sales Territory to non-exclusive distributor of Products
or (ii) terminate this Agreement.

     4.5 Delivery. All deliveries of Products by LifeCell to Distributor hereunder, unless otherwise agreed
to by LifeCell in writing, shall be made in accordance with the Delivery Schedule and shall be FOB [***]. LifeCell agrees to use commercially reasonable efforts to
ship Products in accordance with the Delivery Schedule, but in no event more than ninety (90) days
after

 

			
	[***]	 	Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

-9-

 

LifeCell’s receipt of Distributor’s purchase order, provided that LifeCell timely receives
Distributor’s purchase order issued in accordance with the terms of this Agreement. Distributor
agrees that its only right or remedy for LifeCell’s failure to deliver Products within 90 days of
receipt of Distributor’s applicable and compliant purchase order is as set forth in Section 4.1(c).

     4.6 Regulatory Approval. LifeCell shall be responsible for securing all marketing and other regulatory
approvals and permits necessary or otherwise required in the United States and shall pay for all
costs associated therewith. In the event that the Sales Territory includes jurisdictions outside
of the United States, Distributor shall be responsible for securing all marketing and other
regulatory approvals and permits necessary or otherwise required in any jurisdiction in the Sales
Territory other than the United States in which Distributor intends to distribute Products or is
distributing Products, as the case may be, and shall pay for all costs associated therewith.
Distributor shall provide evidence of its securing all marketing and other regulatory approvals and
permits as set forth in this Section 4.6 promptly upon the request of LifeCell. Upon any
termination or expiration of this Agreement, to the extent transferable by law, Distributor shall
in its sole discretion have the option to enter good faith negotiations with LifeCell to sell
LifeCell all such marketing and other regulatory approvals and permits upon mutually satisfactory
terms and conditions.

     4.7 Storage and Handling. Distributor agrees to store, handle and transport Processed Tissue and
adhere to all applicable record keeping requirements therefor, in strict accordance with all
applicable laws, rules and regulations, including without limitation, the guidelines of the United
States Food and Drug Administration (the “FDA”) and the American Association of Tissue Banks (the
“AATB”) and the specifications and procedures of LifeCell set forth in Schedule I attached to this
Agreement and made apart hereof, as it may be reasonably changed by LifeCell, in its sole
discretion, from time to time. LifeCell agrees to provide Distributor with such advance notice of
any such changes to Schedule II as is commercially reasonable. Upon reasonable notice and during
regular business hours, Distributor shall make available from time to time its storage, handling
and transport facilities for inspection at LifeCell’s expense by independent representatives
selected by LifeCell or qualified LifeCell employees to verify compliance with the applicable
provisions hereof. Distributor shall store Products and sell Products from inventory to Customers
in the Sales Territory on a First In First Out basis.

     4.8 Forecasts; Deliveries; Orders.

          (a) No later than the first day of every Sales Quarter during the Term, Distributor shall
provide to LifeCell an updated rolling forecast for the following twelve (12) month period in the
format typically provided by Distributor prior to the date of this amendment and restatement (each
an “Updated Product Forecast”). Each Updated Product Forecast is subject to LifeCell’s
express written approval unless either (i) the Number of Units of Products in any of the Sizes for
any of the first three Sales Quarters of that respective forecast have increased by less than ten
percent (10%), respectively, from their most recent previously-forecasted amounts, or (ii) the
Number of Units of Products in any of the Sizes for the newly-added fourth Sales Quarter of that
respective forecast exceed those of the forecast’s third Sales Quarter by less than ten percent
(10%). In the event that either (y) an Updated Product Forecast complies with the percentage
requirement set forth in the immediately preceding sentence, or (z) an Updated Product Forecast
that does not comply with such percentage requirement is otherwise approved in writing by LifeCell
pursuant to this Section 4.8(a), it shall be deemed as accepted by LifeCell and Distributor.
Promptly following the Effective Date, the parties will mutually agree on a separate Product
forecast for [***] Sheet Product and Micronized Product through the Wind Down Period

 

			
	[***]	 	Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

-10-

 

reasonably calculated to allow for appropriate depletion of Distributor’s supply of [***] Sheet
Product and Micronized Product by the expiration of the Wind Down Period. Such forecast will be
adjusted by the parties on a monthly basis following the parties mutual review and consideration of
current inventory volumes and customer demand promptly at the end of each month of the Wind Down
Period.

          (b) The Number of Units of Products specified for the first Sales Quarter of each accepted
Updated Product Forecast, (each a “First Quarter Commitment”), shall constitute binding
commitments on behalf of Distributor to purchase from LifeCell and LifeCell to deliver to
Distributor. The Number of Units of each respective Product and Sizes forecasted for the second,
third and fourth Sales Quarters of such product forecasts shall constitute non-binding projections
of anticipated future unit demand until such time, whether subsequently revised pursuant to Section
4.8(a) or left unchanged, each become the unit forecast for the first Sales Quarter of the latest
Updated Product Forecast.

          (c) Purchase orders for the shipment of the number of Units of Products in the Sizes, issued
in conformance with each First Quarter Commitment shall be binding on LifeCell and Distributor,
except as otherwise provided herein. Purchase orders issued for the number of Units of Products in
the Sizes, in excess of the current First Quarter Commitment for the current Sales Quarter shall be
deemed accepted only up to the applicable First Quarter Commitment for that Sales Quarter unless
otherwise expressly acknowledged by LifeCell in writing.

          (d) Distributor agrees to submit to and cause to be received by LifeCell, on or before the
last day of each applicable Sales Quarter in accordance with Section 4.1(a) at LifeCell’s address
set forth in Section 15, written purchases orders for the purchase of a quantity of Units of
Products in the Sizes necessary to at least satisfy the impending First Quarter Commitment for the
next Sales Quarter. Except as otherwise set forth herein, all purchase orders for Numbers of Units
of each respective Product and Sizes in excess of those specified in the current First Quarter
Commitment are subject to approval and written acceptance by LifeCell. Once issued, Distributor
shall not cancel or reschedule any purchase order within twenty (20) days of the scheduled shipment
date for the Products without express written consent from LifeCell. Hand written provisions on
any purchase orders submitted by or through Distributor shall be deemed deleted. Additional or
different terms inserted in this agreement or in any purchase order by either party, or deletions
thereto, whether by alterations, addenda, or otherwise, shall be of no force and effect, unless
mutually expressly agreed to by both parties in writing.

     4.9 Warranty; Limitation of Liability.

          (a) LifeCell represents and warrants that any Processed Tissue delivered by it to Distributor
hereunder will be, and will have been, obtained, processed, stored, handled and transported in
accordance with (i) all applicable legal requirements then in effect, including without limitation,
the regulations of the FDA and the United States Department of Health and Human Services (21 C.F.R.
Part 1270), (ii) the guidelines of the AATB, (iii) the license requirements of the states of New
York, California and Florida, and (iv) the procedures and specifications set forth on Schedule II.
Distributor agrees that the only remedies for failure of any Processed Tissue to comply with this
limited warranty shall be replacement of non-conforming Processed Tissue.

          (b) The parties acknowledge and understand that, under the Federal Food, Drug, and Cosmetic
Act and regulations thereunder, FDA may consider the Processed Tissue or any Products to be medical
devices for the intended uses contemplated in this Agreement, rather than human tissue. The
parties understand, acknowledge and agree that LifeCell does not warrant that the Processed Tissue

 

			
	[***]	 	Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

-11-

 

or any Products currently meet or in the future will be able to meet medical device regulatory
requirements, including, without limitation, obtaining premarket approval. The parties further
understand, acknowledge and agree that the FDA’s imposition of medical device regulatory
requirements would be substantially more burdensome and costly than the FDA’s human tissue
requirements and that, among other things, the FDA could require that a party or the parties take
certain actions with respect to the Processed Tissue or Products regarding premarket approval,
commercial distribution and regulatory requirements that could have a material impact on the
distribution of Products as contemplated by the parties hereunder. In the event that the FDA
imposes medical device regulatory requirements on the Products or Processed Tissue, (i) Distributor
may cancel any pending purchase orders and/or return any inventory in Distributor’s possession in
exchange for a prompt refund by LifeCell to Distributor of the dollar amount equal to the Transfer
Prices paid by Distributor for the Sizes returned multiplied by the number of Units thereof, and
(ii) LifeCell or Distributor may terminate this Agreement upon fifteen (15) days advance written
notice to the other without incurring any further liability under this Agreement.

          (c) In the event and to the extent that any of the actions contemplated by or performed in
connection with this Agreement constitutes the sale of goods by LifeCell, LIFECELL HEREBY DISCLAIMS
AND NEGATES ANY AND ALL WARRANTIES, WHETHER EXPRESS OR IMPLIED WITH RESPECT TO THE PROCESSED
TISSUE, THE PRODUCTS OR ANY RIGHTS HEREUNDER TRANSFERRED, INCLUDING WITHOUT LIMITATION, ANY IMPLIED
WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.

          (d) Distributor covenants and agrees that it shall not make or provide to any Customer any
warranties, representations, specifications, or claims regarding the Processed Tissue or Products
in excess of or inconsistent with those described herein.

          (e) LifeCell will not be liable for indirect, incidental, special, consequential, punitive,
exemplary or multiple damages, including without limitation, any damages resulting from business
interruption, loss of use, loss of business, loss of revenue, or loss of profits, arising in
connection with this Agreement or LifeCell’s performance hereunder or of any other obligations
relating to this Agreement, even if LifeCell has been advised of the likelihood of those damages.
The aggregate liability of LifeCell to Distributor arising directly or indirectly out of this
Agreement shall not exceed [***]. This limitation of liability shall
apply regardless of the cause of action under which those damages are sought. The parties
acknowledge that absent this limitation, LifeCell would not have been able to agree to provide the
Products or perform its other obligations hereunder for the consideration and on the terms and
conditions set forth in this Agreement.

     4.10
Processed Tissue Changes. LifeCell reserves the right at any time to make changes in the Processed
Tissue provided, however, that LifeCell shall use commercially reasonable efforts to
provide [***] prior written notice to Distributor of any such changes. Distributor
agrees that LifeCell shall have no liability to Distributor by reason of any Processed Tissue
change.

     4.11 Processed Tissue Shelf Life. LifeCell covenants that the shelf life of any Processed Tissue
delivered to Distributor during the Term shall have a shelf life of no less than [***] as of the date of shipment from LifeCell.

     4.12 Product Recalls.

          (a) Responsibility for Recall. In the event any Product(s) must be recalled or LifeCell
reasonably determines that it is prudent to have any Product(s) recalled from the channel of
distribution

 

			
	[***]	 	Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

-12-

 

by reason of failure to meet any requirements of law or otherwise, Distributor shall have the
sole responsibility to effect the recall. LifeCell is solely responsible for final decisions
concerning the recall of Products in the United States, and the destruction and/or reconditioning
of recalled Products. In addition, LifeCell is solely responsible for all communications with
Regulatory Agencies concerning Product recalls in the United States. For recall of Product outside
the United States, the parties agree to work cooperatively regarding communication with the
Regulatory Agencies to effect the recall. Any costs and expenses incurred by either party in
connection with a recall of Products shall be borne by the party whose acts or omissions caused or
resulted in the necessity for such recall. LifeCell shall use commercially diligent efforts to
cooperate with Distributor in implementing any such recalls to the extent such cooperation is
necessary to effect the recall.

          (b) Responsibility for Reimbursement. In the event the recall results from or is caused by an
act or omission by Distributor, Distributor shall reimburse LifeCell for any costs and/or expenses
reasonably expended by LifeCell as a consequence of the recall. Without limiting the general
nature of the foregoing, Distributor shall bear the cost of any Products involved in such recall.
In the event the recall results from or is caused by an act or omission by LifeCell, LifeCell shall
reimburse Distributor for any costs and/or expenses reasonably expended by Distributor as a
consequence of the recall. Without limiting the general nature of the foregoing, LifeCell will
provide replacement Products for recalled Products and for any Products that cannot be shipped due
to the condition requiring the recall within 120 days, and if this does not occur, Distributor
shall have the right to terminate this Agreement.

5. Market Development Programs. LifeCell and Distributor shall review the implementation and
administration of market development and regulatory strategies, priorities, of the Products
(“Market Development Programs”) and Clinical Development Programs and activities and procedures
related to the marketing and sales of Products.

6. Term. This Agreement, as amended shall be effective as of April 1, 2004 and, unless earlier
terminated in accordance with the terms pursuant to Section 7, shall remain in force and effect
until 11:59 p.m., Eastern United States time, December 31, 2018 (the “Initial Term”). Not
later than one hundred twenty (120) days prior to the expiration of the Initial Term or then
current Renewal Term, each party shall provide written notice to the other party indicating its
desire to renew this Agreement for a Renewal Term (the “Renewal Notice”). In the event that either
party’s Renewal Notice indicates a desire to renew this Agreement for a Renewal Term, the parties
shall arrange to meet, in person or telephonically, not later than ninety (90) days prior to the
expiration of the Initial Term or then current Renewal Term, and shall negotiate in good faith
concerning the renewal of this Agreement and any revisions to the terms and conditions to this
Agreement. Unless otherwise extended by mutual agreement of the parties, in the event the parties
have not agreed to renew this Agreement prior to September 30 of the last year of the Initial Term
or then current Renewal Term, this Agreement shall terminate upon expiration of the Initial Term or
then current Renewal Term, as the case may be. Each renewal to this Agreement, including any
revisions to this Agreement agreed to between the parties, shall be memorialized in a written
amendment to this Agreement executed by authorized representatives of each of the parties.

7. Termination.

     7.1 Expiration. This Agreement shall terminate on the expiration of the Initial Term or then current
Renewal Term, as applicable, unless the parties shall have agreed to a Renewal Term in accordance
with Section 6.

     7.2 LifeCell Option. This agreement shall terminate, at the option of LifeCell, (i) immediately upon
notice to Distributor in the event of (1) an attempted assignment or delegation of this Agreement
by

-13-

 

Distributor, without LifeCell’s prior written consent, to an entity that is neither controlled
by, nor controls
Distributor via an ownership interest of at least ninety percent (90%), (2) an inability by
Distributor to pay its debts as they become due, (3) the institution of any proceedings by or
against Distributor for reorganization, bankruptcy or other relief under any insolvency or similar
law, (4) an application for or the appointment of a receiver for Distributor (5) dissolution of
Distributor, whether voluntary or by law, unless dissolved into a an entity that is either
controlled by, or controls Distributor via an ownership interest of at least ninety percent (90%),
or (6) solely if LifeCell and KCI Medical Resources are then Affiliates, a material and
intentional breach by Distributor of Section 1B of that certain Trademark License Agreement by and
between Distributor and KCI Medical Resources, dated the Effective Date (the “KCI License
Agreement”) which is not remedied by Distributor within thirty (30) days after written notice
thereof specifying in reasonable detail the nature of the alleged breach, as determined by final
judgment of an arbitrator pursuant to Section 12 of the KCI License Agreement which is no longer
subject to appeal, and provided LifeCell first follows in good faith the dispute resolution
procedures set forth in Section 10D of the KCI License Agreement; or (ii) upon thirty (30) days
written notice to Distributor in the event of a material breach by Distributor of any of the terms
of this Agreement not otherwise described in clause (i) above, if such notice specifies in
reasonable detail the nature of the alleged breach and Distributor shall have failed to cure such a
breach within thirty (30) days of such notice.

     7.3 Other. This Agreement also shall terminate in accordance with other Sections of this Agreement
that permit or provide for such termination, including, without limitation, Sections 4.4, 4.9(b)
and 16.2.

     7.4 Permitted Activities. Distributor agrees that upon termination of this Agreement, LifeCell may, at
its option, (i) ship Products to Distributor with respect to orders from Distributor duly accepted
by LifeCell during the Term, for sale to and payment by Distributor in accordance with the terms of
this Agreement (treating such terms for this limited purpose as being still in effect), and (ii)
permit Distributor to sell Products in Distributor’s inventory on a non-exclusive basis, but
otherwise subject to and in accordance with the terms of this Agreement (treating such terms for
this limited purpose as being still in effect), until the earlier of such time as (1) all of
Distributor’s then existing inventory of Products has been sold, or (2) the Products have reached
their expiration date. Notwithstanding the foregoing, Distributor, at its option, may return to
LifeCell the actual Products last delivered to Distributor in an amount equal to the amount of
Products purchased by Distributor from LifeCell in the immediately preceding Sales Quarter,
provided that those Products returned have a shelf life of no less than nine (9) months when
received by LifeCell and meet the quality requirements applicable thereto, including without
limitation, the requirements of Section 4.7 and Schedule II (the “Put-Back Amount”), and LifeCell
shall refund to Distributor the dollar amount equal to the Transfer Prices paid by Distributor for
the Sizes returned, multiplied by the number of Units thereof. In the event that Distributor, after
the return to LifeCell of the Put-Back Amount, still retains Products in inventory, LifeCell, at
its option, shall either purchase Distributor’s remaining inventory of Products [***] in effect at the time such Products were purchased by Distributor, provided that the
Products to be repurchased by LifeCell have a shelf life of no less than nine (9) months when
received by LifeCell and meet the quality requirements applicable thereto, including without
limitation, the requirements of Section 4.7 and Schedule II, or permit Distributor to sell the
Products in Distributor’s inventory on a non-exclusive basis for the greater of sixty (60) days
after termination of this Agreement, or until all of Distributor’s then existing inventory of
Products has been sold, or the Products have reached their expiration date.

     7.5 Damages.

          (a) Distributor shall not be entitled to and shall not claim or seek indemnification or any
other form of damages or compensation from LifeCell by reason of termination of this Agreement

 

			
	[***]	 	Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

-14-

 

pursuant to its terms or loss of its rights under this Agreement pursuant to such termination, nor
shall it be entitled to seek compensation or damages on account of prospective profits or income after the
termination date.

          (b) LifeCell shall not be entitled to and shall not claim or seek indemnification or any other
form of damages or compensation from Distributor by reason of termination of this Agreement
pursuant to its terms or loss of its rights under this Agreement pursuant to such termination, nor
shall it be entitled to seek compensation or damages on account of prospective profits or income
after the termination date.

     7.6 Distributor Option. This Agreement shall terminate, at the option of Distributor, (i) immediately
upon notice to LifeCell in the event of (1) an attempted assignment or delegation of this Agreement
by LifeCell without Distributor’s prior written consent, (2) an inability by LifeCell to pay its
debts as they become due, (3) the institution of any proceedings by or against LifeCell for
reorganization, bankruptcy or other relief under any insolvency or similar law, (4) an application
for or the appointment of a receiver for LifeCell, (5) dissolution of LifeCell, whether voluntary
or by law or (6) a change in the control of LifeCell reasonably unacceptable to Distributor or (ii)
upon thirty (30) days written notice to LifeCell in the event of a material breach by LifeCell of
any of the terms of this Agreement not otherwise described in clause (i) above, if LifeCell shall
have failed to cure such breach within 30 days of such notice or (iii) upon 60 days prior written
notice to LifeCell in the event that LifeCell changes any of the Products and such changes, in
Distributor’s reasonable judgment, significantly and adversely affect Distributor. In addition to
the foregoing, Distributor shall have the right to terminate this Agreement at any time, for any
reason in its sole discretion, by giving LifeCell written notice of termination not less than
eighteen (18) months prior to the effective date of termination.

     7.7 Survival. Except as otherwise expressly set forth herein, the obligations of the parties under
Sections, 4.1(d), 4.4, 4.7, 4.9, 4.12, 7.4, 8.1, 9, 10, 11, 12, 14, and 17 through 27 shall survive
any expiration or termination of this Agreement forever.

8. Complaints and Regulatory Notices.

     8.1 Complaints.

          (a) In the event that LifeCell or Distributor at any time during the Term receives any
written, electronic or oral communication that alleges deficiencies related to identity, quality,
durability, reliability, safety, effectiveness or performance concerning the Products or Processed
Tissue (individually or collectively, a “Complaint”), including notices from the FDA regarding any
alleged regulatory non-compliance of such Products or Processed Tissue, or the marketing thereof,
such party shall, within two (2) business days following receipt of notices relating to medical
reports and within 2 business days following receipt of any notice relating to any other Complaint
or such shorter period as may be required by applicable laws, rules or regulations, provide to the
other party all information contained in such Complaint, report or notice and any additional
information relating thereto as may reasonably be requested.

          (b) In the event that any Complaint is received from a Customer, LifeCell and Distributor
shall use their best efforts to reach mutual agreement concerning the handling and resolution of
such customer Complaint. LifeCell shall be responsible for the timely review and analysis of each
Complaint, to document its findings in connection therewith and, as LifeCell deems necessary, to
take corrective action.

-15-

 

     8.2 Regulatory Notice. Each of LifeCell and Distributor shall promptly but in no event more than five
(5) days following the receipt thereof, notify the other party and provide to such party a copy or
transcription, if available, of any materially adverse communication received from a regulatory
agency relating to the Product or Processed Tissue, the marketing thereof or any related matter.

9. Trademarks.

     9.1 Definition. Distributor acknowledges that LifeCell owns and shall continue to own all right, title
and interest in and to the trademarks or trade names “AlloDerm,” “LifeCell” and “AlloDerm Process”
(the “Trademarks”).

     9.2 Grant. LifeCell hereby grants to Distributor a non-exclusive license to use the Trademarks during
the Term solely in connection with Distributor’s marketing and sales of the Products to Customers
in the Sales Territory as provided herein and, in those jurisdictions in which Distributor has been
appointed an exclusive distributor pursuant to Section 1.1 and provided Distributor’s
distributorship status has not become nonexclusive, LifeCell agrees not to grant a license to any
other person to use the Trademarks during the Term in connection with marketing and sales of the
Products to Customers in the Sales Territory.

     9.3 Distributor’s Trademarks. The parties acknowledge and agree that all right, title and interest in
and to any trademarks, service marks, trade names or brand names developed for the Product by the
Distributor hereunder shall reside solely with the Distributor. The parties further acknowledge
and agree that the use and display of the trademarks developed by the Distributor and/or LifeCell
Trademarks shall be authorized in advance by LifeCell. The Distributor will provide packaging
specifications, labeling and graphics to LifeCell for review and approval. The parties agree that
the Product package will include a statement, to be agreed upon by both parties, indicating
LifeCell as the manufacturer/technology provider.

     9.4 Limitation of Grant. In performing its obligations hereunder, Distributor may use the Trademarks
only for display on packaging or images of the Products and Processed Tissue. All such use and
display shall be solely in connection with the promotion and solicitation of orders for the
Products to Customers in the Sales Territory and only in such fashion as has been expressly
authorized by LifeCell in advance of such use or display. Distributor acknowledges and agrees that
its use of the Trademarks shall at all times be as licensee for the account and benefit of
LifeCell. To the extent that any rights in and to any of the Trademarks are deemed to accrue to
Distributor pursuant to this Agreement, Distributor hereby assigns any and all such rights, at such
time as they may be deemed to accrue, to LifeCell.

     9.5 Distributor Actions. Distributor shall not, at any time, do or cause to be done any act or thing
that (i) will in any way impair the rights of LifeCell in or to the Trademarks or their
registrations, (ii) may affect the validity of any of the Trademarks or (iii) may depreciate the
value of the Trademarks or their reputation. Except as otherwise specifically provided herein,
Distributor shall not, during the Term or thereafter, attach LifeCell’s title or right in and to
the Trademarks. Distributor shall, at LifeCell’s request and sole expense, provide all
commercially reasonable cooperation and assistance in connection with LifeCell’s efforts to
register, maintain, protect and defend the Trademarks and to prosecute any infringers with respect
to the Trademarks. LifeCell shall control all efforts to register, maintain, protect and defend
the Trademarks and to prosecute any infringers with respect to the Trademarks. Distributor agrees
to advise LifeCell promptly of any actual or potential infringement of the Trademarks on becoming
aware of such infringements. LifeCell shall have the sole right to determine if any action shall
be taken against any third party on account of any such infringements or imitations and Distributor
shall not institute any suit or take any action against any third party on account of any such
infringements or imitations without first

-16-

 

obtaining LifeCell’s written consent to do so. Any
recovery as a result of such action shall belong solely to LifeCell, except to the extent that such
recovery represents damage to Distributor, in which event any specified recovery, net of all
expenses paid by LifeCell, including Distributor’s attorneys’ fees, if any, shall
be paid to Distributor, Distributor agrees and undertakes that its use of the Trademarks will be in
strict compliance with any and all applicable laws, rules and regulations, including trademark
laws, and that it will make such marking on the Product packaging or otherwise in connection
therewith as may be required by LifeCell in its sole discretion. Distributor shall use commercially
reasonable efforts to cooperate fully with LifeCell in preparing and causing to be recorded at
LifeCell’s expense such documents as may be necessary or desirable to evidence, protect and
implement the rights of LifeCell pursuant to this Section 9.

     9.6 Pre-Publication Review of Marketing Materials. All Marketing Materials are expressly subject to
pre-publication review and approval with respect to, but not limited to, content, style,
appearance, composition, timing, and media. Prior to the distribution or publication of any
advertising, technical, sales or other materials containing any of LifeCell’s trademarks, service
marks or trade names, or referring to the Products or Processed Tissue (“Marketing Materials”),
Distributor shall provide one copy of proofs of such Marketing Materials to LifeCell for review and
approval (Attention: Vice-President, Marketing, LifeCell Corporation, One Millennium Way,
Branchburg, NJ 08876) at least ten (10) days prior to the anticipated publication of such Marketing
Materials. LifeCell shall use commercially diligent efforts to provide feedback and/or approval (as
the case may be) to Distributor within five (5) days after LifeCell’s receipt of the applicable
Marketing Materials. Notwithstanding anything to the contrary contained herein, Distributor shall
not use, distribute or publish anything containing LifeCell’s trademarks, service marks or trade
names or referring to Products or Processed Tissue without the express prior written consent of
LifeCell.

     9.7 Termination of Use of Trademark. Except as provided in Section 7.4, if for any reason Distributor
ceases to be the Distributor of the Products in the Sales Territory, Distributor’s right to use the
Trademarks shall terminate immediately upon depletion of existing inventory of Product. Except as
provided in Section 7.4, upon any termination of this Agreement, (i) any and all rights granted to
Distributor hereunder, together with any interest in and to the Trademarks and registrations
therefor which Distributor may be deemed to have acquired by virtue thereof or otherwise, shall
immediately cease and without further act or instrument be assigned to and revert to LifeCell, and
(ii) Distributor shall immediately terminate all further use of the Trademarks except as provided
herein. Thereafter, Distributor shall not recommence or continue using any of the Trademarks
without the prior written consent of LifeCell. In addition, Distributor will promptly execute any
instruments reasonably requested by LifeCell which LifeCell reasonably, in its sole discretion,
deems necessary, proper or appropriate to accomplish or confirm the foregoing. Any such
assignment, transfer or conveyance shall be without further consideration other than the mutual
agreement contained herein.

10. Proprietary Rights. To LifeCell’s knowledge, it owns or possesses, or has licenses or other
rights to use and license all patents, patent applications, patent disclosures and inventions,
patent licenses, trademarks, trade names, trade secrets, service marks, brand marks, brand names,
copyrights, copyright applications, inventions, technologies, know-how, formulae and processes
owned by or licensed to LifeCell (collectively, “Proprietary Rights”) necessary for it to comply
with its obligations under this Agreement without any conflict with or infringement of the rights
of any third party. To LifeCell’s knowledge, no claim has been asserted or threatened by any person
regarding the use or licensing of any of the Proprietary Rights by LifeCell or challenging or
questioning the validity, enforceability or effectiveness of any licenses or agreements relating to
Proprietary Rights or asserting any rights in such Proprietary Rights. To LifeCell’s knowledge,
the use by LifeCell of its Proprietary Rights does not violate

-17-

 

or infringe the rights of any third
party. LifeCell is not aware of any third parties who are infringing or violating any of the
Proprietary Rights.

11. Independent Contractor. Distributor is an independent contractor and agrees not to represent
itself in any manner to any third party as a partner, agent, associate or employee of LifeCell. It
is expressly provided that this Agreement does not create a partnership, joint venture or any similar
business association or combination between the parties hereto. It is understood and agreed that
all contracts for the sale of Products to Customers will be between Distributor (or its permitted
sub-distributors) and Customers. Distributor shall have no authority to accept orders for Products
on behalf of LifeCell. Distributor does not have the power to bind LifeCell or to assume or create
any contract or other obligation on behalf of LifeCell.

12. Indemnity.

     12.1 Distributor. Distributor shall indemnify and hold LifeCell harmless from any and all claims,
liabilities, judgments, losses, damages, costs and expenses, including without limitation,
reasonable attorneys’ fees and costs, (“Damages”) successfully asserted against LifeCell by any
person not a party to this Agreement which Damages result from any bodily injury, illness, death,
or property damage if Damages (i) arise out of any statement, representation, warranty or Marketing
Materials issued by Distributor which materially exceeds in scope or is different in meaning from
statements made by LifeCell in LifeCell’s own literature, or specifications or has been previously
approved by LifeCell or (ii) arises solely from the negligence or wrongful activity of Distributor.

     12.2 LifeCell. LifeCell shall indemnify and hold Distributor harmless from any and all Damages by any
person or entity not a party to this Agreement which Damages result from any bodily injury,
illness, death, or property damage if such Damages arise from (i) a defect in any of the Processed
Tissue associated with any Products, (ii) a failure of any of the Processed Tissue associated with
any Products to meet LifeCell’s specifications, (iii) from the negligence or wrongful activity of
LifeCell or (iv) infringement of Proprietary Rights of third parties.

     12.3 Settlements and Compromises. Neither the party having the right to indemnification nor the party
having the indemnification obligation under this Section 12 may settle or compromise any such
claim, suit, action or proceeding unless (i) the other party consents in writing (which consent may
not be unreasonably withheld) and (ii) the terms of that settlement or compromise release the other
party from any and all liability with respect to that claim.

     12.4 Joint Actions. In the event any claim, suit, action or proceeding is asserted against both
LifeCell and Distributor, or one party to this Agreement joins the opposite party in any such
claim, suit, action or other proceeding, a party will be obligated to indemnify the opposite party
with respect to that matter only if, and in proportion to the extent that, such party is first
found to have been at fault with respect to that matter by a final, non-appealable judgment of a
court of law.

13. Compliance with Laws.

          (a) Each of LifeCell and Distributor shall comply with, and be responsible for ensuring that
its employees and agents comply with, all applicable statutes, rules, regulations, orders and
by-laws of the federal government of the United States and any other jurisdiction in the Sales
Territory or any state and any agency, authority or political subdivision thereof.

-18-

 

          (b) Distributor agrees that neither it nor any of its officers, directors, employees or
representatives will, directly or indirectly, in connection with the solicitation of sales of the
Products to Customers in the Sales Territory:

          (i) make any payment to any officer or employee of any government, or to any political
party or official thereof; where such payment either is unlawful under laws applicable
thereto, or would be unlawful under the Foreign Corrupt Practices Act of 1977, as amended,
of the United States of America, if Distributor, as the case may be, were a “domestic
concern”, within the meaning of such act;

          (ii) make any payment to any person, if such payment constitutes an illegal bribe,
illegal kickback or other illegal payment under laws applicable thereto; or

          (iii) commit, directly or indirectly, any other act or omission in violation in any
material respect of any applicable law, regulation, rule or custom having the effect of law.

14. Confidential Information.

     14.1 Definition. LifeCell and Distributor may from time to time provide to the other party (each, a
“Recipient”) certain advice, technical information, know-how and other proprietary data and
information that they respectively own to aid each other in the performance of their respective
obligations under this Agreement. Inasmuch as various of these materials and advice (all of which
will be referred to herein as the “Confidential Information”) will contain confidential information
and/or trade secrets, it is hereby agreed that any Confidential Information which is disclosed by
one party to the other is valuable, proprietary property belonging to the party making such
disclosure, and the Recipient agrees that it will neither use nor disclose any Confidential
Information to any third party (except if necessary in the performance of its duties hereunder),
except with the prior written consent of the other party, provided, however, that any written
Confidential Information shall be marked “Confidential”.

     14.2 Limitation. The Recipient agrees to make copies of that Confidential Information received by the
Recipient as is authorized by the other party and which is necessary to the performance of
Recipient’s obligations under this Agreement. Recipient also agrees to limit disclosure of the
Confidential Information to only those employees of Recipient with a need to know such Confidential
Information in connection with the performance of Recipient’s obligations under this Agreement.

     14.3 Remedies. In the event of breach or threatened breach by the Recipient or its employees of any of
the provisions of Sections 14.1 or 14.2, the other party shall be entitled to an injunction or
judicial order equivalent thereto restraining the Recipient or its employees from disclosing, in
whole or in part, such Confidential Information. Nothing herein shall be construed as prohibiting
the other party from pursuing any other remedies available to it for such breach or threatened
breach, including recovery of damages from the Recipient.

     14.4 Termination. The Recipient agrees, either upon the termination of this Agreement or upon request,
to surrender to the other party all documentary material including Confidential Information, price
lists, catalogues, technical literature, sales literature, samples and any other documents, papers
or other properties of the other party, however previously supplied to the Recipient by the other
party, provided, however, that Distributor may retain a reasonable amount of Marketing Materials as
necessary to sell Products in accordance with Section 7.4. The Recipient may retain one (1) copy or
memorandum of said documentary materials for dispute resolution purposes only.

-19-

 

     14.5 Survival. The obligations of the Recipient pursuant to this Section 14 shall continue in full
force and effect after the termination of this Agreement regardless of how or when this Agreement
is expires or is terminated.

     14.6 Exclusions. Notwithstanding any other provision in this Section 14, the term “Confidential
Information” does not include information which (i) came into the Recipient’s possession prior to
execution of this Agreement, provided that such information is not known by the Recipient to be
subject to another confidentiality agreement with or other obligation of secrecy to the other
party, or (ii) becomes generally available to the public other than as a result of a disclosure by the Recipient
or any of the Recipient’s directors, officers, employees, agents or advisors, or (iii) becomes
available to the Recipient on a non-confidential basis from a source other than the other party or
the other party’s advisors, provided that such source is not bound by a confidentiality agreement
with or other obligation of secrecy to the other party.

15. Notices. Any notice, transmittal of documents, correspondence or other communication between the
parties to this Agreement required hereunder shall be in writing, addressed to the party to whom
sent and transmitted by certified mail, courier or by facsimile with signed written original to
follow by certified mail or courier. All such notices in compliance with this provision shall be
deemed received by the other party on the next business day after transmission. For purposes of
this Agreement, the addresses of the parties are as follows until changed by written notice from
the party desiring to change its address to the other party.

	 	 	 

	If to LifeCell:

	 	If to Distributor:
	 
	 	 
	LifeCell Corporation 

One Millennium Way 

Branchburg, NJ 08876

Attn: President 

Telephone: 908-947-1102

Facsimile: 908-947-1081

	 	Wright Medical Technology, Inc. 

5677 Airline Road 

Arlington, TN 38002

Attn: President 

Telephone: 901-867-4361

Facsimile: 901-867-4332
	 
	 	 
	With a copy to:
	 	 
	 
	 	 
	LifeCell Corporation 

One Millennium Way 

Branchburg, NJ 08876

Attn: Legal Department 

Telephone: 908-947-1118

Facsimile: 908-947-1081

	 	Wright Medical Technology, Inc. 

5677 Airline Road 

Arlington: TN 38002

Attn: General Counsel 

Telephone: 901-867-4743

Facsimile: 901-867-4398

16. Force Majeure.

     16.1 Definition. Neither party hereto shall be responsible for any loss or damage to the other in the
event that it is unable to fulfill the whole or any part of its obligations hereunder, or is
prevented or delayed from fulfilling the same, due to war or hostilities (whether war be declared
or not), invasion, act of foreign enemies, rebellion, revolution, insurrection, military usurpation
of power, civil war or riot, strike, lockout, commotion, disorder, flood, tempest, earthquake, acts
or omissions of civil or military authority whether legitimate or not, or other causes beyond the
control of either party, including changes in laws or regulations relating to or affecting the
Processed Tissue or the Products and increase in costs of raw materials resulting in commercial
impracticability of selling Products [***].

 

			
	[***]	 	Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

-20-

 

     16.2 Consequences. Upon the occurrence of an event of force majeure, the party affected shall notify
the other party immediately. The rights and obligations of either party under this Agreement
affected by any such event of force majeure shall be suspended only for the duration and to the
extent of such event of force majeure, and once such event of force majeure ceases to exist, the
rights and obligations of the parties shall continue in full force. In the event that a condition
of force majeure sufficient to suspend a party’s obligations under this Agreement is continuing for
a period of ninety (90) days or more, either party may terminate this Agreement immediately upon
written notice to the other party.

17. Arbitration.

     17.1 Agreement. Any dispute, controversy, claim or other matter in question between the parties hereto
arising out of or relating to this Agreement or any other document or instrument executed by the
parties hereto in connection with this Agreement contemplated in any of the foregoing, including
all issues of fact and law (for the purposes of this Section 17, the “Claim”), shall be settled by
arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration
Association (the “Commercial Arbitration Rules”), except as otherwise expressly set forth herein.
Without limiting the generality of the foregoing, “Claims” shall also include any dispute,
controversy, claim or other matter in question arising out of or related to this Agreement or any
document or instrument executed by the parties hereto in connection herewith, it being the purpose
and intent hereof to evidence the agreement of all the parties hereto to submit all Claims to
arbitration. Notice of demand for arbitration shall be filed in writing with all parties to this
Agreement as to whom the Claim is alleged and with the American Arbitration Association (the
“AAA”). The arbitration proceeding shall be conducted by one disinterested neutral arbitrator who
shall be appointed from a panel in accordance with the Commercial Arbitration Rules of the AAA;
provided, however, that if a neutral arbitrator cannot be selected and appointed by the parties to
the dispute from the first list of names submitted by the AAA, then the AAA shall submit to each
party to the dispute a second list of names of persons chosen from the panel, and if a neutral
disinterested arbitrator cannot be appointed for any reason from said second list, then the AAA
shall then be deemed authorized and directed to and shall select and appoint, on behalf of all
parties to the dispute, one disinterested neutral arbitrator (but in no event shall the AAA appoint
an arbitrator whose name has previously been rejected by the parties to the dispute). All persons
submitted as prospective arbitrators by the AAA shall be persons having substantial knowledge of
substantive commercial laws and the general issues in question for arbitration.

     17.2 Proceedings. The arbitrator shall conduct the arbitration proceeding in the State of New Jersey if
the Distributor initiates the dispute and in Memphis, Tennessee if LifeCell initiates the dispute,
as provided hereinabove and in the Commercial Arbitration Rules. The arbitrator rendering the
judgment or award shall deliver a brief written opinion explaining such judgment or award and the
legal and factual reasons therefor. This agreement to arbitrate shall be specifically enforceable
under applicable law in any court having jurisdiction thereof. The award rendered by the
arbitrator shall be final, such judgment shall be entered upon it in accordance with applicable law
in a court hearing jurisdiction thereof and any such award or judgment shall be subject to appeal
in accordance with the same procedures and an the same legal basis as a final judgment of the trial
court in which such judgment is entered. The parties hereto agree to expedite and cooperate in
obtaining the entry of judgment with respect to such award. A demand for arbitration shall be made
within a reasonable time after the Claim or other matter in question has arisen. In no event shall
the demand for arbitration be made after the date when institution of legal or equitable
proceedings based on such Claim or the matter would be barred by applicable statutes of limitation.

-21-

 

18. Definitions and Construction.

     18.1 Certain Definitions. Capitalized terms used in this Agreement, unless the context otherwise
requires, have the meanings specified in this Section 18.1 or in the part of this Agreement
referred to below.

          (a) “AAA” shall have the meaning given to such term in Section 17.

          (b) “AATB” shall have the meaning given to such term in Section 4.7.

          (c) “Agreement” shall have the meaning given to such term in the preamble and shall for all
purposes include the Schedules and Exhibits hereto.

          (d) “Agreement Matters” shall have the meaning given to such term in Section 19.

          (e) “Affiliate” means, with respect to any specified person at any time, any person who is
directly or indirectly controlling, controlled by or under common control with such specified
person at such time.

          (f) “Claim” shall have the meaning given to such term in Section 17.1.

          (g) “Clinical Development Programs” means the conduct, in the United States and outside the
United States, as applicable, of preclinical and clinical activities and filing and prosecution of
regulatory applications in support of regulatory approval and regulatory classification in respect
of commercial introduction, marketing and sales of the Products.

          (h) “Commercial Arbitration Rules” shall have the meaning given to such term in Section 17.1.

          (i) “Complaint” shall have the meaning given to such term in Section 8.1.

          (j) “Confidential Information” shall have the meaning given to such term in Section 14.1.

          (k) “Customer” means health care provider who or that performs orthopedic surgery procedures
including, but not limited to, the spine, trauma, oncology, extremities and joint replacement, or,
until June 30, 2011, podiatric wound surgical procedures or other care or treatment of podiatric
wounds.

          (l) “Damages” shall have the meaning given to such term in Section 12.1.

          (m) “ “Distributor” shall have the meaning given to such term in the preamble.

          (n) “Effective Date” shall have the meaning given to such term in the opening paragraph of
this Agreement.

          (o) “FDA” shall have the meaning given to such term in Section 4.7.

          (p) “Initial Term” shall have the meaning given to such term in Section 6.

          (q) “Intellectual Property” means United States and foreign patents and patent applications,
know-how, show-how, trade secrets, inventions, discoveries and technical information,

-22-

 

including
without limitation, information embodied in drawings, designs, copyrights, copyright applications,
trademarks and trademark applications, service marks and service marks applications, material
specifications, processing instructions, formulas, equipment specifications, product
specifications, confidential data, computer software, electronic files, research notebooks,
invention disclosures, research and development reports and the like related thereto and all
amendments, modifications and improvements of any of the foregoing.

          (r) “LifeCell” shall have the meaning given to such term in the preamble.

          (s) “Market Development Programs” shall have the meaning given to such term is Section 5.

          (t) “Marketing Materials” shall have the meaning given to such term in Section 9.6.

          (u) “person” means any individual, corporation, partnership, joint venture, association,
limited liability company, joint stock company, trust, unincorporated organization or any federal,
state, local or other government (or agency or political subdivision thereof).

          (v) “Processed Tissue” means tissue processed by LifeCell in accordance with its proprietary
AlloDerm® process.

          (w) “Products” means all Processed Tissue provided during the Term in the form of (i)
LifeCell’s current human acellular [***] dermal sheet product for use in any and all orthopedic
surgical applications and, until the expiration of the Wind Down Period, LifeCell’s current human
acellular [***] and [***] sheet product in podiatric wound applications, with the exception that
the marketing of product by Distributor for use in [***] (“Sheet Products”), [***]; and
(ii) until June 30, 2011, LifeCell’s current acellular, micronized form, specifically limited to
use in [***] (“Micronized Products”). Products are further described in the Product Specification
as detailed hereto as Schedule II, which may be changed to include additional Products, as they are
developed by LifeCell and made available to Distributor in accordance with the provisions of this
Agreement or otherwise by mutual agreement of the parties. Distributor agrees that it shall not
sell or distribute Products for any non-orthopedic application, or as otherwise limited by or
excluded in the definition above, except that Distributor may sell or distribute the Product for
podiatric wound applications until the expiration of the Wind Down Period.

          (x) “Proprietary Rights” shall have the meaning given to such term in Section 10.

          (y) “Recipient” shall have the meaning given to such term in Section 14.1.

          (z) “Renewal Notice” shall have the meaning given to such Term in Section 6.

          (aa) “Renewal Term” means any and each additional [***] term of this Agreement mutually
agreed to by the parties.

          (bb) “Revenue Share Payments” shall have the meaning given to such term in Section 4.3.

 

			
	[***]	 	Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

-23-

 

          (cc) “Sales Quarter” means any three month period or shorter period, as the case may be,
occurring during the Term that commences on the first day of each calendar quarter and terminates
on the earlier of the first day of the immediately following calendar quarter or on the date this
Agreement expires or is terminated.

          (dd) “Sales Territory” means the United States, Greece, Italy, South Africa, Canada, and the
United Kingdom as well as any other country or jurisdiction which the parties mutually agree by
written amendment to this Agreement is to be included in the Sales Territory; provided, however,
that Distributor shall have the first option to exclusively distribute the Products in other
countries or jurisdictions which right shall be lost if Distributor fails to sell the Product in such
additional countries or jurisdictions within [***] of LifeCell’s reasonable request.

          (ee) “Sales Year” means any twelve (12) month or shorter period, as the case may be, occurring
during the Term that commences on the Effective Date or the anniversary of the Effective Date, as
the case may be, and terminates on the earlier of the date 12 months thereafter or on the date this
Agreement expires or is terminated.

          (ff) “Sizes” means the sizes in which the Products are offered for sale as set forth in the
most current Updated Product Forecast.

          (gg) “Term” means the Initial Term and each Renewal Term, if any.

          (hh) “Trademarks” shall have the meaning given to such term in Section 9.1.

          (ii) “Transfer Prices” shall have the meaning given to such term in Section 4.2.

          (jj) “Units” means the number of Products to be purchased by Distributor for a respective
Sales Quarter as set forth in the most current Updated Product Forecast.

          (kk) (pp) “Updated Product Forecast” shall have the meaning given to such term in Section
4.8(a).

     18.2 Other Definitions. Other terms may be defined elsewhere in this Agreement and shall have the
meanings there indicated.

     18.3 Gender, etc. Words used in this Agreement, regardless of the number or gender specifically used,
shall be deemed and construed to include any other number, singular or plural, and any other
gender, masculine, feminine or neuter, as the context shall require.

     18.4 Certain Constructions. As used in this Agreement, unless expressly stated otherwise, references
to:

          (a) (i) “include” and “including” mean “include, without limitation” and “including, without
limitation”, respectively, (ii) the words “hereof’, “herein” and “hereunder”, and similar words,
refer to this Agreement as a whole and not to any particular section, subsection, paragraph or
provision of this Agreement and (iii) “or” means “either or both”,

          (b) Unless otherwise specified, all reference in this Agreement to sections, subsections,
paragraphs or schedules are deemed references to the corresponding sections, subsections,
paragraphs or schedules in this Agreement.

 

			
	[***]	 	Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

-24-

 

          (c) References to “days”, “months”, “quarters” and “years” in this Agreement, unless
otherwise specifically indicated, shall mean calendar days, months, quarters and years,
respectively,

     18.5 Captions. The section, subsection and paragraph headings contained herein are for convenience of reference
only and shall not affect or control the construction or interpretation of any provision hereof.

19. Governing Law and Jurisdiction. The validity, interpretation, performance, and enforcement of
this Agreement and all matters arising directly and indirectly from this Agreement (collectively
“Agreement Matters”) shall be governed by the internal laws of the State of Delaware, without
regard to any conflicts or choice of law rules. The parties hereby irrevocably submit to the
exclusive personal jurisdiction of the State and Federal courts located in Delaware for the purpose
of any suit, action, proceeding or judgment which, directly or indirectly, arises out of any
Agreement Matters; provided that a party to this Agreement shall be entitled to enforce an order or
judgment of a Delaware court (or a federal appellate court of competent jurisdiction issuing the
same on appeal from a Delaware court) in any other court having jurisdiction over the other party
hereto. Each of the parties hereby irrevocably waives, to the fullest extent permitted by
applicable law, any objection that it may now or hereafter have to the laying of the venue of any
such proceeding brought in such a court and any claim that any such proceeding brought in such a
court has been brought in an inconvenient forum.

20. Public Announcements. Unless otherwise required by applicable laws, rules or regulations of any government, agency or
political subdivision thereof or the rules of any securities exchange or market on which such
party’s securities are listed, neither party shall issue a press release or make any public
announcement relating to this Agreement or the transactions contemplated hereby or subsequent
developments relating to the relationship of the parties hereto without first providing a copy of
such release or announcement to the other party and the prior consent of the other party, which
consent shall not be unreasonably withheld. In the case of any announcement required by applicable
laws, rules or regulations of any government, agency or political subdivision, thereof or the rules
of any securities exchange or market on which such party’s securities are listed, neither party
shall issue a press release or make any public announcement relating to this Agreement or the
transactions contemplated hereby or subsequent developments relating to the relationship of the
parties hereto without first providing a copy of such proposed announcement to the other party as
soon as practicable prior to the proposed release thereof.

21. Amendment; Remedies; Waiver. This Agreement may be amended, modified, superseded, canceled, renewed or extended, and its
terms and conditions may be waived, but only by a written instrument signed by the parties or, in
the case of a waiver, by the party waiving compliance. All remedies available to either party for
breach of this Agreement are cumulative and may be exercised concurrently or separately. Exercise
of any one remedy shall not be deemed an election of such remedy to the exclusion of other
remedies. No delay on the part of any party in exercising any right, power or privilege hereunder
shall operate as a waiver thereof, nor shall any waiver on the part of any party of any right,
power or privilege hereunder, nor any single or partial exercise of any right, power or privilege
hereunder, preclude any other or further exercise thereof or the exercise of any other right, power
or privilege which that party might otherwise have hereunder, or at law or in equity.

22. Severability. Should any provision of this Agreement be held unenforceable or invalid, then the parties hereto
agree that such provision shall he deemed modified to the extent necessary to render it lawful and
enforceable, or if such a modification is not possible without materially altering the intention of
the parties hereto, then such provision shall be severed herefrom. In such case the validity of
the

-25-

 

remaining provisions shall not be affected and this Agreement shall be construed as if such
provision were not contained herein.

23. Assignment. Other than as expressly set forth herein, neither party shall assign or subcontract the whole or
any part of this Agreement without the other party’s written consent.

24. Entire Agreement. All agreements and understandings between the parties relating to the purchase and distribution
of the Products in the Sales Territory are embodied in this Agreement. This Agreement supersedes
any previous agreements and understandings between the parties as to the subject matter hereof and
is entire in itself and not a part of any other agreement, and no promises, covenants, or
representations of any kind or nature other than those expressly stated herein have been made to
induce either party to enter into this Agreement. All other terms and conditions, whether express,
or implied by statute, common law, trade usage or custom are hereby excluded and extinguished.

25. Construction of Agreement. Both parties have participated fully in the preparation and revision of this Agreement. Any
rule of construction to the effect that ambiguities are to be resolved against the drafting party
shall not apply to the interpretation of this Agreement.

26. Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an
original and all of which together shall constitute one and the same instrument.

27. Further Assurances. Each party will do such further acts, including executing and delivering additional agreements
or instruments as the other may reasonably require, to consummate, evidence, confirm or give effect
to the agreements contained in this Agreement.

(Remainder of page intentionally left blank)

-26-

 

     IN WITNESS WHEREOF, the parties hereto, by their duly authorized representatives, have
executed and delivered this Agreement as of the date first above written.

	 	 	 	 	 
	 	LIFECELL CORPORATION

 	 
	 	By:  	/s/ Lisa Colleran           1-28-11	 
	 	 	Name:  	Lisa Colleran 	 
	 	 	Title:  	President 	 
	 
	 	WRIGHT MEDICAL TECHNOLOGY, INC

 	 
	 	By:  	/s/ Gary D. Henley
 	 
	 	 	Name:  	Gary D. Henley 	 
	 	 	Title:  	CEO 	 
	 

Attachments:

	 	Schedule I — Processed Tissue Storage, Handling and Transportation Specifications and
Procedures
	 
	 	Schedule II — Product Specification

-27-

 

Schedule I

Processed Tissue Storage, Handling and Transportation Specifications and Procedures

The following policies and procedures to be incorporated into Distributor’s existing protocols are
based on the Standards of the American Association of Tissue Banks (1998) and specifically address
the issue of “Tissue Distribution Intermediates” (Section M). Technical assistance is available
from LifeCell to facilitate the incorporation of these procedures.

Appropriate documentation is critical. Particular attention should be paid to the following areas:

Documentation of receipt of tissue

Lot/graft numbers

Expiration date

Received by

Date of receipt

Condition of packaging

Documentation of storage conditions

Temperature monitoring

Documentation of distribution

     Distributor shall maintain distribution records that permit the tracing of the Processed
Tissue to the consignee. Distribution records must include:

Date of order

Consignee name and address

Identification of person placing the order

Type and quantity of tissue ordered

Information regarding tissue shipped

Identification numbers of tissue’s

Expiration date of tissue Date of shipment

Mode of transportation

Name of Individual filling order

Documentation of final package inspection prior to distribution

Additional requirements:

Storage Equipment

Distributor must insure that all storage equipment (i.e., refrigerator(s)) is regularly maintained
(i.e. preventative maintenance program), calibrated, and monitored.

Monitoring of refrigerators may consist of the installation of a continuous temperature recording
device or a routine (once each working day) and documented check of temperature utilizing a
refrigerator thermometer. Acceptable temperature range for the storage of Processed Tissue is 1 -
10°C. Processed

-28-

 

Tissue may be stored in a standard household refrigerator provided that this temperature range can
be maintained.

Adverse Outcomes

All reports of complaints or adverse outcomes must be required to be forwarded immediately to
LifeCell.

Return of Tissue

All expired, returned, damaged, or otherwise compromised packages or grafts must be returned to
LifeCell.

Labels

Packages containing Processed Tissue cannot be relabeled. Existing labeling cannot be altered.

-29-

 

Schedule II

Product Specification

See attached.

 

 

			
	Wright Medical Technology
	 	Document No.: PS02-0013
	Issued
	 	Rev.: 07

Product Specification for GRAFTJACKET®

Regenerative Tissue Matrix

	 	 	 

	Revision Draft Date:

	 	July 26, 2007
	Issue Date:

	 	July 31, 2007
	Effective Date:

	 	July 31, 2007
	Supersedes:

	 	PS02-0013, Rev.: 06
	Supersedes Date:

	 	January 25, 2007

	 	 	 

	Prepared by:

	 	Mandy Turner, Product Development Engineering
	 
	 	 
	Approved by:

	 	Ann Burgess, Biologics Development
	 
	 	 
	 

	 	Barbara Blum, Material Engineering
	 
	 	 
	 

	 	Connie Howell, Industrial Engineering
	 
	 	 
	 

	 	Eric Gay, Marketing
	 
	 	 
	 

	 	Brian Young, Regulatory Affairs
	 
	 	 
	 

	 	Sam Wheeler, International Marketing
	 
	 	 
	 

	 	Phil Ward, Production Management
	 
	 	 
	 

	 	Tim Smith, Process Engineering
	 
	 	 
	 

	 	Rodney Williams, Quality Assurance
	 
	 	 
	 

	 	Scott Shankle, Quality Engineering
	 
	 	 
	 

	 	Carey Michael, Purchasing
	 
	 	 
	 

	 	Joel Batts, Clinical
	 
	 	 
	 

	 	Denise Carey, Sterilization Assurance
	 
	 	 
	 

	 	Andy Fronk, Packaging Engineering
	 
	 	 

Document Release Section

	 	 	 	 	 
	Dept/Function	 	Approver	 	Signature and Date
	 
	 	 	 	 
	Documentation

	 	Lori Oliver
	 	/s/ Lori Oliver                                  7-31-2007

			
	 	 	 
	
Proprietary Information

Do not copy or write on this document.

	 	Page 1 of 5

 

 

			
	Product Specification for GRAFTJACKET® Regenerative Tissue Matrix

Issued
	 	Document No.: PS02-0013

Rev.: 07

	1.0	 	Objective
	 
	 	 	This specification describes the product requirements for GRAFTJACKET®
Regenerative Tissue Matrix (manufactured by LifeCell Corporation, Branchburg, NJ).
	 
	2.0	 	Document Reference Summary

	 	•	 	American Association of Tissue Banks (AATB): Standards for Tissue Banking Guidelines
	 
	 	•	 	21 CFR 1271, Subpart C — Eligibility Determination for Donors of Human Cells,
Tissues, and Cellular and Tissue-Based Products
	 
	 	•	 	21 CFR 1271, Subpart D — Current Good Tissue Practice for Human Cell, Tissue, and
Cellular and Tissue-Based Product Establishments.
	 
	 	•	 	G102-0163 Package Challenge/Distribution Testing Procedure

	3.0	 	Product Description

	 	3.1	 	General Overview: GRAFTJACKET® is human dermal tissue that has been
processed to remove all epidermal and dermal cells while maintaining its biologic
matrix. It is provided freeze-dried and must be rehydrated prior to use. Once
rehydrated, the product may be sutured, folded, or easily trimmed with scissors or a
scalpel in the operating room.
	 
	 	3.2	 	Intended Use: The GRAFTJACKET® matrix is used to provide supplement
support, protection, and reinforcement of tendon and ligamentous tissue; to be used as
a periosteal patch or covering; or for protection and support of bone and tendons in
hand surgery.
	 
	 	3.3	 	Related Devices: There are no related devices.
	 
	 	3.4	 	Post-market Surveillance: Post-market surveillance will be investigated
through complaint history, surgeon feedback, and/or clinical evaluations of both WMT
and related competitor products.

	4.0	 	Proposed Size Offering

	 	4.1	 	GRAFTJACKET® matrix will have multiple size offerings ranging from 1
to 5 cm in width to 4 to 12 cm in length.
	 
	 	4.2	 	GRAFTJACKET® matrix may have specific size options with the
approximate dimensions of 5 X 5 cm (approximately 2” X 2”), 5 X 10 cm (approximately 2”
X 4”), 2 X 4 cm (approximately 0.8” X 1.6”), 4 X 7 cm (approximately 1.6” X 2.8”), and
1 X 12 cm (0.4” X 4.7”).
	 
	 	4.3	 	GRAFTJACKET® matrix will have different thicknesses ranging from
0.013” to 0.099”.
	 
	 	4.4	 	GRAFTJACKET® matrix may have different thickness ranges for specific
size options:

	 	4.2.1	 	The average sheet thickness for the standard
GRAFTJACKET® matrix 5 X 5 cm, 4 X 7 cm, and 5 X 10 cm sizes may fall
in the range of 0.035” to 0.060”.
	 
	 	4.2.2	 	The average sheet thickness for the thin GRAFTJACKET®
matrix 2 X 4 cm size may fall in the range of 0.013” to 0.024”.
	 
	 	4.2.3	 	The average sheet thickness for the thick
GRAFTJACKET® matrix 2 X 4 cm, 5 X 5 cm, and 4 X 7cm sizes may fall in
the range of 0.040” to 0.070”.
	 
	 	4.2.4	 	The average sheet thickness for the ultra thick
GRAFTJACKET® matrix 4 X 7 cm size may fall in the range of 0.071” to
0.099”.
	 
	 	4.2.5	 	The average sheet thickness for the long strip
GRAFTJACKET® matrix 1 X 12 cm size may fall in the range of 0.050” to
0.075”.

	 	4.5	 	Each size will be provided for single patient use in packaged, sealed containers.

			
	 	 	 
	Proprietary Information

Do not copy or write on this document.
	 	Wright Medical Technology

Page 2 of 5

 

 

			
	Product Specification for GRAFTJACKET® Regenerative Tissue Matrix

Issued
	 	Document No.: PS02-0013

Rev.: 07

	5.0	 	Product Features and Functional Requirements

	 	5.1	 	Product thickness shall be determined by LifeCell Corporation in the dry state
per their standard procedure.
	 
	 	5.2	 	Product sheets shall be visibly uniform in appearance and white or buff
colored.
	 
	 	5.3	 	The donor tissue shall be recovered in accordance with FDA regulations and AATB
guidelines. Donor history and tissues shall be examined to rule out pathogenic
contamination.
	 
	 	5.4	 	The material shall be processed to ensure there is no damage to the underlying
matrix of the tissue. The patented LifeCell process shall remove epidermal and dermal
cells, while preserving the collagen, elastin, blood vessel channels, and proteoglycan
proteins.
	 
	 	5.5	 	Material shall be biocompatible and conducive to cellular and vascular infiltration.
	 
	 	5.6	 	Residual moisture of the material shall be less than ≤ 6%.
	 
	 	5.7	 	The product is supplied freeze-dried.
	 
	 	5.8	 	Functional requirements

	 	5.8.1	 	Fixation for GRAFTJACKET® shall be compatible with
current surgical techniques such as sutures, surgical tacks, etc.
	 
	 	5.8.2	 	Rehydrated product shall be flexible and malleable for surgical manipulation.
	 
	 	5.8.3	 	If not totally saturated, GRAFTJACKET® readily
absorbs fluids such as saline, blood, cells, or marrow.
	 
	 	5.8.4	 	GRAFTJACKET® shall resist tearing and deformation in both wet and dry states.

	6.0	 	Materials and Processes

	 	6.1	 	Manufacturing Processes

	 	6.1.1	 	Human dermal tissues from which GRAFTJACKET® is
produced shall be procured in accordance with FDA regulations and AATB
guidelines.
	 
	 	6.1.2	 	Dermal and epidermal cells shall be removed and the product
freeze-dried by LifeCell Corporation per their patented processes.
	 
	 	6.1.3	 	GRAFTJACKET® shall be certified to conform to the
appropriate WMT material specification upon receipt.

	 	6.2	 	Packaging

	 	6.2.1	 	GRAFTJACKET® shall be packaged with one piece of
unattached, non-woven backing that is clearly labeled to indicate that it must
be removed, except for size options less than 2 cm wide which will not have a
backing (i.e., the long strip GRAFTJACKET® matrix, 1 X 12 cm).
Removal should occur after partial rehydration.
	 
	 	6.2.1	 	GRAFTJACKET® shall be packaged in clean, heat-sealed
peel pouches, freeze-dried, and sealed within a foil inert atmosphere.
	 
	 	6.2.2	 	Labeling shall clearly indicate that the inner pouch and contents are not sterile.

			
	 	 	 
	Proprietary Information

Do not copy or write on this document.
	 	Wright Medical Technology

Page 3 of 5

 

 

			
	Product Specification for GRAFTJACKET® Regenerative Tissue Matrix
	 	Document No.: PS02-0013
	Issued
	 	Rev.: 07

	6.0	 	Materials and Processes (continued)

	 	6.3	 	Sterilization

	 	6.3.1	 	The tissues shall be prepared aseptically.

	 	6.3.1.1	 	Product shall be aseptically prepared in a controlled area.
	 
	 	6.3.1.2	 	Representative samples of the final product tested from the donor lot
must be free of bacterial and fungal pathogens using microbiological
tissue cultures in accordance with AATB guidelines.
	 
	 	6.3.1.3	 	All processing shall be done in conjunction with antibiotics.
Antibiotics utilized in transport or processing of the tissue are to
appear on the final labeling.

	7.0	 	Product Performance Specifications

	 	7.1	 	Performance Requirements

	 	7.1.1	 	Products must meet appropriate FDA regulations and AATB guidelines.
	 
	 	7.1.2	 	The aseptically prepared product shall have an expiration date
of two years from the date of manufacture, clearly indicated on the package.
	 
	 	7.1.3	 	GRAFTJACKET® may be transported in ambient
temperature, then refrigerated immediately on receipt to maximize the shelf
life. Unopened product shall be stored under refrigeration at 1 to 10°C
(34-50°F). Per the manufacturer, temperature fluctuations during shipping will
not affect the product adversely.
	 
	 	7.1.4	 	Packaging components must pass the challenge/distribution test
per the WMT document G102-0163, Package Challenge/Distribution Testing
Procedure.
	 
	 	7.1.5	 	Prior to use, GRAFTJACKET® must be rehydrated. At
least 200 ml of rehydration fluid (sterile normal saline or sterile lactated
Ringer’s solution) must be used. GRAFTJACKET®, with backing, must be
submerged for at least five minutes in a dish of 100 ml of rehydration fluid.
After five minutes the backing must be removed, and the product submerged for an
additional five minutes in a separate dish of 100 ml of rehydration fluid. When
fully rehydrated, the product is soft and pliable throughout.
	 
	 	 	 	NOTE: Thicker grafts may take up to 30 minutes or longer to completely
rehydrate. The ultra thick GRAFTJACKET® matrix may take up to 1
hour or longer to completely rehydrate.
	 
	 	7.1.6	 	GRAFTJACKET® shall be easily sutured without tearing.

	 	7.2	 	[***]

	8.0	 	Clinical and Regulatory Plan

	 	8.1	 	Clinical Evaluation Requirements
	 
	 	 	 	Clinical evaluation will be undertaken after commercialization as defined by the
clinical & regulatory, research & development, marketing groups, and surgeon
consultants.

			
	 	 	 
	Proprietary Information
	 	Wright Medical Technology
	Do not copy or write on this document.
	 	Page 4 of 5

 

			
	[***]	 	Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

 

 

			
	Product Specification for GRAFTJACKET® Regenerative Tissue Matrix
	 	Document No.: PS02-0013
	Issued
	 	Rev.: 07

	8.0	 	Clinical and Regulatory Plan (continued)

	 	8.2	 	Regulatory Clearance/Approvals

	 	8.2.1	 	GRAFTJACKET® is regulated by the FDA in accordance
with 21 CFR, Part 1271, as human tissue for transplantation.
	 
	 	8.2.2	 	This product will be selectively registered outside the US by a
joint determination of International Marketing, Regulatory Affairs, and LifeCell
Corporation.

	9.0	 	Production Launch and Distribution Logistics

	 	9.1	 	GRAFTJACKET® Regenerative Tissue Matrix was launched in the U.S. in
the third quarter of 2002. The thin GRAFTJACKET® Matrix 2 X 4 cm product was
launched in the fourth quarter of 2003. The thick GRAFTJACKET® Matrix 4 x 7
cm product was distributed in the fourth quarter of 2003. The thick
GRAFTJACKET® Matrix 2 x 4 cm was available in the first quarter of 2005.
The thick GRAFTJACKET® Matrix 5 x 5 cm product was distributed in the first
quarter of 2005. The ultra thick GRAFTJACKET® Matrix 4 x 7 cm product was
launched in the second quarter of 2005. The thick GRAFTJACKET® Matrix 4 x 7
cm product was available in the first quarter 2007. The long strip
GRAFTJACKET® Matrix 1 X 12 cm product will be launched in the fourth quarter
of 2007.
	 
	 	9.2	 	Launch support materials will include brochures, surgical techniques,
informational videos, press releases, etc. Product usage training will be conducted in
regional training sessions.
	 
	 	9.3	 	This product will be selectively launched outside the US by a joint determination of International
Marketing and Regulatory Affairs.

	10.0	 	Production Costs

	 	10.1	 	Material transfer costs are outlined in the effective Supply and Development
Agreement between LifeCell Corporation and Wright Medical Technology.

	11.0	 	Document Changes
	 
		 	(02) Material Change
	 
	 	 	Approvals            Added Carely Michael and removed Shannon Cummings.
	 
	 	 	Added new product size to the Product Specification.

	 	Section 3.2 	 	Updated Intended for Use section per the current IFU.
	 
	 	Section 3.4 	 	Added post-market surveillance.
	 
	 	Section 4.0 	 	Broadly defined possible product sizes and thickness ranges.
	 
	 	Section 4.1 	 	Added new product size dimensions.
	 
	 	Section 4.2 	 	Added thickness range for new product size.
	 
	 	Section 5.1 	 	Deleted specific thickness specifications for specific products. This
information is part of the Material Specification.
	 
	 	Section 5.6 	 	Updated a residual moisture content of 5% to £ 6%.
	 
	 	Section 6.2.1 	 	Indicated new product(s) may not have a non-woven backing.
	 
	 	Section 8.2.2 	 	Added “and LifeCell Corporation.”

	 
	 	Section 9.1 	 	Updated for previous launches and planned launch of new product size.

			
	 	 	 
	Proprietary Information
	 	Wright Medical Technology
	Do not copy or write on this document.
	 	Page 5 of 5

 

 

Document Distribution Summary Sheet

	 	 	 

	Document

Contact

	 	Upon receipt of a new controlled document, put document into documentation book and shred
obsolete document (when new document is a revision). Inform appropriate personnel of the revisions made, or of
the new document.
	 
	 	 
	Document No:

	 	PS02-0013
	Revision:

	 	07
	Issued Date:

	 	July 31, 2007
	Document Title:

	 	
Product Specification for GRAFTJACKET® Regenerative Tissue Matrix

Initial distribution of the document indicated above is to the following locations:

	 	 	 	 	 	 	 
	Distribution Location	 	Code	 	Contact/Backup
	 
	 	 	 	 	 	 
	Writer

	 	DDF
	 	Mandy Turner
	 
	 	 	 	 	 	 
	C&RA

	 	 	012	 	 	Cherita Walton/Angela Smith
	 
	 	 	 	 	 	 
	R&D Hips and Knees

	 	 	016	 	 	Maleesha Morris
	 
	 	 	 	 	 	 
	Bio. Development Lab

	 	 	026	 	 	Linda Morris
	 
	 	 	 	 	 	 
	Mat./Process Research

	 	 	065	 	 	Maleesha Morrisexv10w2

Exhibit 10.2

CONFIDENTIAL

TRADEMARK LICENSE AGREEMENT

     THIS TRADEMARK LICENSE AGREEMENT (the “Agreement”) is effective as of January 28, 2011 (the
“Effective Date”) by and between Wright Medical Technology Inc., a Delaware corporation located at
5677 Airline Road, Arlington, Tennessee, 38002 (“Licensor”) and KCI Medical Resources, an unlimited
company organized and existing under the laws of Ireland, but resident in the Cayman Islands, with
its principal place of business located at Zephyr House, Mary Street, P.O. Box 709 GT, Grand
Cayman, Cayman Islands (“Licensee”).

     WHEREAS, Licensor is the owner of all right, title and interest in, to and under the marks
listed on Exhibit A attached hereto and any variants thereof and any application and registrations
therefor, together with any foreign counterparts thereof (the “Licensed Marks”);

     WHEREAS, Licensee is desirous of using the Licensed Marks identified in the attached Exhibit A
in connection with its wound care business;

     NOW THEREFORE, for and in full consideration of the mutual promises contained herein, and
other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
the parties mutually agree as follows:

1. License Right Granted.

     A. Licensor hereby grants to Licensee, and Licensee accepts, upon the terms and conditions set
forth herein, a non-transferable, non-sublicensable, [***] license (the
“License”) to use the Licensed Marks in connection with the marketing, sale, distribution and
provision of any of Licensee’s soft tissue graft containment products, excluding all such products
that are [***], commercialized in the Wound Care Field (the “Licensed Goods”). The “Wound Care
Field” shall mean the care and treatment of acute, surgical, and chronic wounds, such as, by
non-limiting example, diabetic foot ulcers, venous leg ulcers, and pressure ulcers. Subject to the
provisions of Section 3 below, Licensee may change the branding of any of its products in the Wound
Care Field without the consent of Licensor. Any use by Licensee of the Licensed Marks outside of
the Wound Care Field or in connection with soft tissue graft containment products that are [***],
shall require prior written approval of Licensor, which consent may be withheld by Licensor for any
reason in its sole discretion. Any use by Licensor of the Licensed Marks inside of the Wound Care
Field or in connection with soft tissue graft containment products that are [***] shall require
prior written approval of Licensee, which consent may be withheld by Licensee for any reason in its
sole discretion. Subject to the provisions of Section 10 below, Licensee’s rights to use the
Licensed Marks shall extend beyond the end of the royalty period.

B. Licensor shall not promote, market, solicit or otherwise participate in the sale of soft tissue
graft containment products in the Wound Care Field during the period from June 30, 2011, until
[***]; provided, however, that Licensee acknowledges that Licensor shall have the right
to continue to promote, market, solicit or otherwise participate in the sale of current and future
products based on its [***] platform currently marketed
and sold under the name Biotape (the “WMT Porcine Platform”) to the hospital market, provided that
Licensor will not, and will not permit, authorize, or license any third party to, begin commercial
sales of any new products based on the WMT Porcine Platform (i.e. products not sold by Licensor as
of the Effective Date) that are specifically indicated for the Wound Care Field to the hospital
market prior to the [***] anniversary of the Effective Date (the “Exclusion Period”). For the
avoidance of doubt, the “hospital market” shall not

 

			
	[***] 	 	Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

 

 

include the post acute wound care market, including, without limitation, wound care facilities,
outpatient facilities, or ambulatory surgical centers. Notwithstanding the provisions of this
Section, it is understood and agreed that if Licensor or Licensor’s orthopedic human derived tissue
product line or business is acquired by an entity that is already engaged (either directly or
through one or more of its affiliates) in the business of manufacturing, marketing, selling,
distributing or providing human derived tissue products in the Wound Care Field at the time of the
acquisition, the restrictions set forth in this paragraph will not apply to such acquirer or its
other affiliates after the closing date of such acquisition, but all other rights and obligations
of Licensor and Licensee shall continue under this Agreement except that Licensee shall have no
obligation to make payment of any amounts due to Licensor under Sections 5 and 6 that become due
after the closing date of such acquisition.

     C. (i) Each party shall promptly notify the other party in writing if it becomes aware of any
infringement, or suspected or threatened infringement of the Licensed Marks in the Wound Care
Field.

          (ii) In the event of any infringement, or suspected or threatened infringement of the Licensed
Marks in the Wound Care Field, Licensee shall have the right and option (but not the obligation) to
institute and control a legal action to prosecute, settle or compromise such infringement (an
“Infringement Action”); provided, however, that Licensee shall not settle or compromise any
Infringement Action for which it assumes responsibility pursuant to this Section that imposes any
obligation on Licensor or that would legally impair the Licensed Marks, without the prior written
consent of Licensor, which consent shall not be unreasonably withheld or delayed. In furtherance
of the foregoing, Licensee may include Licensor as a party in any such Infringement Action, and
Licensor shall (at Licensee’s expense) join such Infringement Action at the direction of Licensee
and provide reasonable cooperation to Licensee in any such Infringement Action. Licensee shall
bear all costs and expenses of any Infringement Action for which it assumes responsibility pursuant
to Section.

          (iii) If Licensee fails or elects not to commence or continue prosecution or defense of an
Infringement Action within thirty (30) days after a written request from Licensor, Licensor may do
so at any time thereafter upon written notice thereof to Licensee; provided, however, that Licensor
shall not settle or compromise any Infringement Action for which it assumes responsibility pursuant
to this Section that imposes any obligation on Licensee or that impairs Licensee’s exclusive rights
under this Agreement to use the Licensed Marks in the Wound Care Field, without the prior written
consent of Licensee, which consent shall not be unreasonably withheld or delayed. Licensee shall
cooperate fully in any such Infringement Action controlled by Licensor, including, if requested by
Licensor, being named as a party in any such Infringement Action. Licensor shall bear all costs
and expenses of any Infringement Action for which it assumes responsibility pursuant to Section.

          (iv) Any and all recoveries or reimbursements from any Infringement Action, if any, shall be
divided between the parties as follows:

	 	(a)	 	first, each party shall be reimbursed for any
and all costs and expenses it incurred in connection with such action;
	 
	 	(b)	 	next, as to any compensatory or punitive or
willful damages or any award of attorneys’ fees in excess of the amount
paid to the parties as reimbursement of costs and expenses pursuant to
the preceding subparagraph, (1) Licensor shall retain any such excess
in any Infringement Action for which it assumes responsibility pursuant
to this Section, and (2) Licensee shall retain any such excess in any

-2-

 

	 	 	 	Infringement Action for which it assumes responsibility pursuant to
this Section.

     D. Without limiting the restrictions applicable to the Licensor during the Exclusion Period as
set forth in Section 1B above, Licensor hereby grants to Licensee a right of first refusal to
obtain exclusive rights to market, sell and distribute in the Wound Care Field any new products
developed by Licensor after the Effective Date based on the WMT Porcine Platform for
commercialization in the Wound Care Field (each a “New Porcine Product”) as follows:

          (i) If at any time prior to the earlier of [***] or the termination of this
Agreement, Licensor undertakes to commercialize any New Porcine Product in the Wound Care Field,
Licensor shall give Licensee written notice of such commercialization (the “New Product Notice”)
not less than [***] prior to the first commercial sale of such New Porcine Product in the Wound
Care Field. If Licensee in interested in obtaining exclusive rights to market, sell and distribute
such New Porcine Product in the Wound Care Field, Licensee shall give written notice thereof to the
Licensor within [***] following its receipt of the New Product Notice (the “Notice of Interest”),
and Licensor and Licensee shall thereafter use reasonable, good faith efforts to negotiate a
Distribution Agreement granting Licensee exclusive distribution rights with respect to such New
Porcine Product in the Wound Care Field on mutually agreeable terms and conditions. If Licensee
fails to deliver a Notice of Interest within [***] following its receipt of the New Product
Notice, Licensee will be deemed to have irrevocably waived its right of first refusal hereunder
with respect to such New Porcine Product.

          (ii) If Licensee delivers a Notice of Interest with respect to a New Porcine Product within [***] following its receipt of the New Product Notice but the parties are unable, after good faith
efforts, to negotiate a Distribution Agreement with respect to such New Porcine Product on mutually
agreeable terms and conditions pursuant to Section 1D(i) above within [***] after Licensee’s
receipt of the Notice of Interest, Licensor shall be free to commercialize such New Porcine Product
in the Wound Care Field without granting distribution rights to Licensee; provided, however, that
prior to granting distribution rights with respect to any such New Porcine Product in the Wound
Care Field to any unaffiliated third party, Licensee shall have a right of first refusal with
respect to such distribution rights as provided in Section 1D(iii) below.

          (iii) Unless Licensee’s right of first refusal hereunder has been waived pursuant to the last
sentence of Section 1D(i) above, the Licensor shall, prior to entering into any agreement with an
unaffiliated third party granting to such party distribution rights with respect to a New Porcine
Product in the Wound Care Field, deliver a written notice to the Licensee setting forth in
reasonable detail the terms and conditions of the proposed agreement with such third party and
offering to enter into a distribution agreement with Licensee on substantially the same terms and
conditions (the “ROFR Notice”). If the Licensee desires to accept such offer, it must deliver
written notice of acceptance to Licensor within [***] following its receipt of the ROFR Notice.
If Licensee delivers notice of acceptance of such offer within the prescribed [***] period, the
Licensor and the Licensee shall enter into a distribution agreement on substantially the same terms
and conditions set forth in the ROFR Notice. If Licensee declines such offer or fails to deliver
written notice of acceptance within the prescribed [***] period, then Licensee’s right of first
refusal hereunder shall be deemed to have been waived and Licensor shall have the right thereafter
to proceed with and enter into a distribution agreement with any unaffiliated third party with
respect to the subject New Porcine Product in the Wound Care Field on terms and conditions no less
favorable to such third party than those described in the ROFR Notice. If at any time subsequent
to Licensee’s rejection of or failure to accept such offer Licensor proposes to enter into a
distribution agreement with an unaffiliated third party with respect to the subject New Porcine
Product in the Wound Care Field on terms and conditions more favorable to such third party than
those set forth in the ROFR

 

			
	[***]	 	Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

-3-

 

Notice, Licensor shall be required to offer such more favorable terms and conditions to
Licensee in accordance with the provisions of this paragraph.

     For the avoidance of doubt, should Licensee waive its right of first refusal as set forth
above during the Exclusion Period, the restriction against Licensor commercializing, or permitting,
licensing, or authorizing a third party to commercialize, any new products based on the WMT Porcine
Platform that are specifically indicated for the Wound Care Field to the hospital market shall
continue in full force and effect through the Exclusion Period.

2. Ownership of the Licensed Marks. Licensee acknowledges that Licensor is the owner of
the Licensed Marks and of the goodwill associated therewith, and that Licensee has acquired and
will acquire no right, title, interest or claim of ownership in or to the Licensed Marks, apart
from the specific license granted herein. All use of the Licensed Marks by Licensee including any
goodwill in connection with the Licensed Marks shall inure to the benefit of Licensor.

3. Quality Standards for Licensed Marks. Licensor shall have the right to exercise
commercially reasonable quality control over Licensee’s use of the Licensed Marks to protect the
goodwill associated with the Licensed Marks. Licensee shall use commercially reasonable efforts to
ensure that all Licensed Goods bearing the Licensed Marks (i) shall be of a standard of quality
that is no less than the standard of quality of Licensed Goods offered by Licensee in the Wound
Care Field as of the date of execution of this Agreement, and (ii) comply with all legal
requirements applicable thereto. Any and all usage of the Licensed Marks by Licensee shall comply
with the trademark usage guidelines and requirements attached hereto as Exhibit B, which may not be
modified or supplemented by the Licensor without the prior written approval of Licensee, unless
required by law to preserve the Licensed Marks or Licensor’s rights therein (the “Usage
Guidelines”). Upon the request of Licensee, Licensor shall use commercially reasonable efforts to
register with the United States Patent and Trademark Office any representation of the Licensed
Marks or derivative or compound thereof which is created by Licensee and consistent with the Usage
Guidelines (the “Derivative Marks”), provided that Licensee pays or reimburses Licensor (at
Licensor’s option) for all costs and expenses thereof, each of which shall be licensed under this
Agreement pursuant to Section 1. Any and all use of the Licensed Marks, in any representation,
form or format, shall inure to Licensor’s benefit, and shall be the sole property of the Licensor;
provided, however, that Licensor shall not have any right to use, license, or exercise any rights
under the Derivative Marks during the term of this Agreement in the Wound Care Field. Licensee
shall use commercially reasonable efforts to maintain or enhance the quality, style and
presentation associated with the Licensed Marks. Licensee shall comply with all notice and marking
requirements of any law or regulation applicable to its use of the Licensed Marks.

4. Marketing/Training Support and Sales Data. Licensor shall, during the period from the
Effective Date through December 31, 2011 (the “Transition Period”), use commercially reasonable
efforts to transition sales activity associated with products branded with the Licensed Marks in
the Wound Care Field to Licensee, as more particularly described in Exhibit D attached hereto and
incorporated herein for all purposes. During the Transition Period, Licensor and Licensee shall
collaborate on sales activity for products branded with the Licensed Marks in the Wound Care Field
with a view toward transitioning Licensor’s customers of products branded with the Licensed Marks
in the Wound Care Field to Licensee. Such collaboration shall not prevent: (i) either party from
independently making sales during the period from the Effective Date through [***] (the
“Wind Down Period”); or (ii) Licensee from independently making sales for the remainder of the
Transition Period and thereafter. Licensor makes no representations or warranties that any of its
customers will transition to Licensee. Licensor will have no obligation to Licensee if any or all
of such customers elect not to do so. For avoidance of doubt, Licensor may continue to make sales
of products branded with the Licensed Marks in the Wound Care Field during the Wind Down Period;
provided, however, that Licensor may not sell any products branded with the

 

			
	[***]	 	Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

-4-

 

Licensed Marks in the Wound Care Field to any new customers or accounts after the [***] following the Effective Date. Following the [***] after the Effective Date,
Licensor agrees to promptly communicate any new customer and sales leads to Licensee for human soft
tissue graft containment products in the Wound Care Field. Except as set forth in Section 1B,
after [***], Licensor shall not, and shall not authorize its distributors to, promote,
market, solicit or participate in any sales of soft tissue graft containment products, whether
branded with the Licensed Marks or otherwise, in the Wound Care Field, and shall not call on
podiatrists or wound care centers in connection with any sales of products branded with the
Licensed Marks for use in the Wound Care Field. For the avoidance of doubt, Licensor shall cease
selling the product SKUs identified in Exhibit C and Licensor shall not knowingly sell any [***]
product SKUs in the Wound Care Field, except as set forth in Section 1B.

Licensor agrees to provide Licensee with copies of all materials and data in its possession
associated with the use of products branded with the Licensed Marks in the Wound Care Field
according to the transition plan set forth in Exhibit D, and shall cease all use of such materials
in the Wound Care Field on or before [***]. Any updates to such materials created by
Licensor during the Transition Period shall be promptly provided to Licensee upon creation. All
rights to use, copy, distribute, and create derivative works of such materials and data in the
Wound Care Field are hereby assigned by Licensor to Licensee.

5. License Payment/Milestone.

     A. In further consideration for the licensed rights granted herein and the Licensor’s
agreement to perform its transition related obligations set forth in Section 4 hereof, the parties
agree that Licensee shall pay $8,500,000.00 (U.S. Dollars) to Licensor by wire transfer of
immediately available funds to an account designated by Licensor as follows:

(i)
$5,500,000.00 (U.S. Dollars) shall be paid to the Licensor on the Effective Date; and

(ii)
$3,000,000.00 (U.S. Dollars) on the one year anniversary of the Effective Date, provided
Licensor does not breach its obligations under this Agreement in any material respect and
fail to remedy such breach within thirty (30) days after written notice thereof from
Licensee specifying in reasonable detail the nature of the alleged breach, or if such breach
cannot reasonably be remedied within thirty (30) days, as soon as practical, so long as
Licensor is diligently pursuing such remedy.

     B. Further, Licensee shall make an additional license payment to Licensor of $[***] (U.S.
Dollars) if Licensee achieves annual sales of Licensed Goods that Licensee brands with the Licensed
Marks representing Gross Revenue (as defined in Section 6) in the amount of $[***] (U.S. Dollars)
during [***], which amount shall be paid to the Licensor on or before February 1,
[***], by wire transfer of immediately available funds to an account designated by Licensor.

6. Royalty.

     A. In further consideration for the licensed rights granted herein, the parties agree that
Licensee shall make the following royalty payments to Licensor for Licensee’s use of the Licensed
Marks. In each case, the royalty for any period shall be calculated based on Gross Revenue (as
defined below) from sales made by Licensee or its affiliates during such period of Licensed Goods
that Licensee brands

 

			
	[***] 	 	Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

-5-

 

with one or more of the Licensed Marks:

	 	(i)	 	[***]% of Gross Revenue during the calendar [***];
	 
	 	(ii)	 	[***]% of Gross Revenue in the calendar [***];
	 
	 	(iii)	 	[***]% of Gross Revenue in the calendar [***];
	 
	 	(iv)	 	[***]% of Gross Revenue in the calendar [***];
	 
	 	(v)	 	[***]% of Gross Revenue in the calendar [***] through the term of the Agreement.

     As used herein, Gross Revenue means the gross sales price of Licensed Goods invoiced by
Licensee or its affiliates to the purchasers of such of Licensed Goods, less the following amounts
to the extent appropriately documented and actually paid out by Licensee or credited against the
amounts received by Licensee in connection therewith: (1) royalties required to be paid by Licensee
to unaffiliated third parties in connection with intellectual property rights in the subject
Licensed Goods licensed by Licensee pursuant to a written license agreement between Licensee and
such unaffiliated third party; (2) industry standard discounts, rebates and deductions actually
given to customers (including group purchasing organizations) based on volumes and/or revenues
commercialized, or any other deductions or the like allowed to wholesalers or distributors or to
other customers for quantity purchases, prompt payments or other industry standard special
conditions; (3) credits, allowances or refunds actually allowed or taken, not exceeding the
original invoice amount, for returned or deficient goods or services, in each case only to the
extent reasonable and standard in the industry; (4) transportation expenses, including any and all
carriage or insurance charges, packaging, freight, and costs of delivery, to the extent separately
identified on the applicable invoice and actually paid by the purchaser; and (5) sales and use
taxes and other fees or taxes imposed by any government or governmental agency, including, but not
limited to any import, export or customs duties but excluding any taxes on the income of Licensee,
in each case to the extent separately identified on the applicable invoice and actually paid by the
purchaser. For purposes of calculating royalties due hereunder, sales will be deemed to have been
made on the date of invoice..

     B. Royalties shall be due and payable on a quarterly basis within forty-five (45) days after
the last day of each calendar quarter, based on the Gross Revenue for Licensed Goods invoiced by
Licensee during the applicable period. With each royalty payment, the Licensee shall deliver to
the Licensor a full, accurate and detailed written accounting showing the sales (by customer) on
which the royalty payment for the subject period was based, and such other information as Licensee
may reasonably require to calculate or verify the amount of royalties due to it hereunder.

     C. The Licensee shall maintain complete and accurate books and records with respect to all
sales for which royalties are due hereunder in sufficient detail to enable the Licensor to compute
and verify such royalties. The Licensor or its representative or agent shall have the right, at
Licensor’s own expense but no more than once during any twelve-month period, to examine and copy,
upon not less than three (3) business days prior written notice and during normal business hours,
such books and records for the purpose of verifying Licensee’s compliance with the provisions of
this Section. In the event that any such audit reveals that Licensee failed to pay any amount due
hereunder, Licensee shall promptly pay Licensor the full amount of such shortfall. If such audit
reveals an underpayment by Licensee of more than [***] for the period under audit,
Licensee will also reimburse Licensor for the reasonable out-of-pocket costs of such audit.

 

			
	[***]	 	Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

-6-

 

     D. Notwithstanding the foregoing, Licensee may terminate its obligation to pay royalties
pursuant to this Section 6 if Licensor breaches in any material respect its obligations under
Section 1B above and fails to remedy such material breach within thirty (30) days after written
notice thereof from the Licensee describing in reasonable detail the nature of the alleged breach,
which termination will be effective upon Licensee’s giving written notice thereof after said thirty
(30) day cure period while such breach is continuing. For avoidance of doubt, Licensee’s
termination of its obligation to pay royalties pursuant to this paragraph will not operate as a
termination of Licensee’s license to use the Licensed Marks hereunder or any other provision of
this Agreement.

7. Warranties.

A. Licensor represents and warrants that it is the sole and exclusive owner of the Licensed
Marks and that, to its knowledge, any registration of the Licensed Marks is valid and
subsisting. Licensor represents and warrants that Licensee’s use of the Licensed Marks as
permitted under this Agreement will not infringe the rights of any third party. Licensor
represents and warrants that it has the authority to enter into this Agreement, license the
rights granted hereunder, and to otherwise perform its obligations hereunder, and Licensor’s
entry into this Agreement or performance of obligations hereunder is not in violation of any
agreement or other instrument to which it is a party or by which it may be bound. Licensor
further warrants that no consent from any third party is necessary for Licensee to license
the rights granted hereunder or use the materials provided by Licensor pursuant to Section
4.

B. Licensee represents and warrants that it has the authority to enter into this Agreement
and to perform its obligations hereunder, and Licensee’s entry into this Agreement or
performance of its obligations hereunder is not in violation of any agreement or other
instrument to which it is a party or by which it may be bound.

C. Licensor represents and warrants that, as of the date of this Agreement: (i) the clinical
study that supports reimbursement of Licensor’s soft tissue graft containment products sold
by Licensor as of the Effective Date, in the Wound Care Field does not rely upon fraudulent
data; and (ii) the submissions made to third parties by Licensor to obtain reimbursement for
Licensor’s soft tissue graft containment products sold by Licensor as of the Effective Date,
in the Wound Care Field do not contain any misstatements of a material nature, in either
case in such a manner or to such an extent that would cause Medicare or private insurers to
discontinue reimbursement for purchases of Licensed Goods. The sole and exclusive remedy
for breach of this warranty shall be for Licensor to provide reasonable assistance to
Licensee to remedy the breach, but in no event shall such reasonable assistance exceed [***]
in the aggregate for all such breaches.

8. Assignment.

Licensee may not assign, transfer, or otherwise dispose of any of its rights or obligations under
this Agreement, by operation of law or otherwise, without the prior written consent of Licensor;
provided, however, that Licensee (A) may freely assign this Agreement to a current or future
“Affiliate” (as hereinafter defined), provided that Licensee will remain jointly and severally
liable for any breach of this Agreement by such Affiliate following any such assignment; and (B)
may assign this Agreement to and have this Agreement assumed by an unaffiliated acquirer or
successor of Licensee in connection with a merger, acquisition, reorganization or restructuring of
the Licensee, or sale by the Licensee of substantially all assets related to this Agreement. As
used herein, the term “Affiliate” means, with respect

 

			
	[***] 	 	Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

-7-

 

to any specified person or entity at any time, any person or entity who is directly or indirectly
controlling, controlled by or under common control with such specified person or entity at such
time.

9. Confidential Information.

     A. Definition. Licensor and Licensee may from time to time provide to the other party
(each, a “Recipient”) certain advice, technical information, know-how and other proprietary data
and information that they respectively own to aid each other in the performance of their respective
obligations under this Agreement. Inasmuch as various of these materials and advice may contain
confidential information and/or trade secrets (all of which will be referred to herein as the
“Confidential Information”), it is hereby agreed that any Confidential Information which is
disclosed by one party to the other is valuable, proprietary property belonging to the party making
such disclosure, and the Recipient agrees that it will neither use nor disclose any Confidential
Information to any third party (except if necessary in the performance of its duties hereunder),
except with the prior written consent of the other party, provided, however, that any written
Confidential Information shall be marked “Confidential”. Information and materials assigned and
provided by Licensor to Licensee under Section 4 shall be deemed to be Confidential Information of
Licensee.

     B. Limitation. The Recipient agrees to make copies of that Confidential Information
received by the Recipient as is authorized by the other party and which is necessary to the
performance of Recipient’s obligations under this Agreement. Recipient also agrees to limit
disclosure of the Confidential Information to only those employees of Recipient with a need to know
such Confidential Information in connection with the performance of Recipient’s obligations under
this Agreement.

     C. Exclusions. Notwithstanding any other provision in this Section, the term
“Confidential Information” does not include information which (i) came into the Recipient’s
possession prior to execution of this Agreement, provided that such information is not known by the
Recipient to be subject to another confidentiality agreement with or other obligation of secrecy to
the other party, or (ii) becomes generally available to the public other than as a result of a
disclosure by the Recipient or any of the Recipient’s directors, officers, employees, agents or
advisors, or (iii) becomes available to the Recipient on a non-confidential basis from a source
other than the other party or the other party’s advisors, provided that such source is not bound by
a confidentiality agreement with or other obligation of secrecy to the other party; or (iv) was
independently developed by the Recipient without reference to or use of any Confidential
Information of the other party.

10. Termination.

     A. The Licensor shall have the right, effective upon the giving of written notice of
termination to the Licensee, to terminate this agreement and the rights and license granted to
Licensee hereunder in any of the following events:

	 	(i)	 	if the Licensee breaches this Agreement in any material respect, and fails to
remedy such breach within thirty (30) days after written notice thereof from the
Licensor specifying in reasonable detail the nature of the alleged breach, or, in the
event that such breach cannot reasonably be remedied within thirty (30) days, as soon
as practical, so long as Licensee is diligently pursuing such remedy, and solely
provided that Licensor first goes through the resolution procedure set forth in Section
10.D; or
	 
	 	(ii)	 	(a) solely provided LifeCell Corporation and Licensee remain Affiliates, if
LifeCell Corporation (or any successor to LifeCell Corporation’s rights and obligations
under the Supply Agreement that is an Affiliate of Licensee):

-8-

 

	 	(1)	 	materially and intentionally breaches Section 3.1(i)
(Exclusivity) of the Supply Agreement, and fails to remedy such material breach
within thirty (30) days after written notice thereof from the Licensor
specifying in reasonable detail the nature of the alleged material breach, or,
in the event that such breach cannot reasonably be remedied within thirty (30)
days, as soon as practical, so long as Licensee is diligently pursuing such
remedy, as each of the foregoing is determined by final judgment of an
arbitrator pursuant to Section 17 of the Supply Agreement which is no longer
subject to appeal, and provided that Licensor first goes through the resolution
procedure set forth in Section 10.D; or
	 
	 	(2)	 	intentionally and materially breaches its obligation to supply
Product (as defined in the Supply Agreement) to Licensor in accordance with the
Supply Agreement on a repeated or continuing basis, and fails to remedy such
breach within thirty (30) days after written notice thereof, or, in the event
that such breach cannot reasonably be remedied within thirty (30) days, as soon
as practical, so long as Licensee is diligently pursuing such remedy, as each
of the foregoing is determined by final judgment of an arbitrator pursuant to
Section 17 of the Supply Agreement which is no longer subject to appeal and
provided that Licensor first goes through the resolution procedure set forth in
Section 10.D (provided, however, that Licensor shall not be entitled to
terminate this Agreement pursuant to this Section 10A(i)(2) if the reason for
LifeCell Corporation’s failure to supply Product is due to a significant
interruption in its production activities which is the result of causes that
are beyond LifeCell’s reasonable control (e.g. unavailability of raw materials
or regulatory intervention) and Licensor’s supply of Products is not impacted
any worse than any other customer of LifeCell purchasing comparable products).

     B. The Licensee shall have the right, effective upon the giving of written notice of
termination to the Licensor, to terminate this agreement in any of the following events:

	 	(i)	 	if the Licensor breaches this Agreement in any material respect, and fails to
remedy such breach within thirty (30) days after written notice thereof from the
Licensee specifying in reasonable detail the nature of the alleged breach, or, in the
event that such breach cannot reasonably be remedied within thirty (30) days, as soon
as practical, so long as Licensee is diligently pursuing such remedy, and solely
provided that Licensee first goes through the resolution procedure set forth in Section
10.D.

     C. Upon termination of this Agreement, all rights and licenses granted to the Licensee
pursuant to this Agreement and all other rights and obligations of the parties shall terminate,
except that: (i) the parties shall not be relieved of any obligations accruing before the effective
date of termination, and (ii) the rights and obligations of the parties under Sections 2, 5, 6C, 9,
10C, 11, 12 and 13 will survive the termination or expiration of this Agreement in accordance with
their respective terms.

     D. If either party believes the other party has breached this Agreement or if a dispute
otherwise arises under this Agreement, a party may deliver a written notice of a dispute to the
other party. If such dispute has not been resolved within thirty (30) days of receipt of such
written notice, an executive of each party shall meet in person at the facilities of the party
receiving such written notice in an attempt to resolve such dispute. If such dispute is not
resolved within a further thirty (30) days, the chief executive officer of each party shall meet in
person at the facilities of the party delivering such notice in a further attempt to resolve such
dispute. If such dispute remains unresolved for a further thirty (30) days, the non-breaching
party may terminate this Agreement pursuant to this Section 10.

-9-

 

11. Indemnification.

     A. By Licensor. Licensor shall indemnify, defend and hold harmless Licensee and its
subsidiaries and affiliates and each of their respective directors, officers, employees and agents
for, from and against all claims, demands, actions, suits, proceedings, losses, damages,
liabilities, costs and expenses (including but not limited to reasonable attorneys’ fees) arising
out any breach of a warranty hereunder or any product bearing a Licensed Mark that is sold or
distributed by Licensor or its affiliates, including but not limited to any failure of such product
to comply with applicable laws or regulations, or from bodily injury, personal injury or product
liability claims resulting from the use of such product, excluding only any claims caused by the
Licensee.

     B. By Licensee. Licensee shall indemnify, defend and hold harmless Licensor and its
subsidiaries and affiliates and each of their respective directors, officers, employees and agents
for, from and against all claims, demands, actions, suits, proceedings, losses, damages,
liabilities, costs and expenses (including but not limited to reasonable attorneys’ fees) arising
out any product bearing a Licensed Mark that is sold or distributed by Licensee or its affiliates,
including but not limited to any failure of such product to comply with applicable laws or
regulations, or from bodily injury, personal injury or product liability claims resulting from the
use of such product, excluding only (i) any third party claims that any use by Licensee of the
Licensed Marks in accordance with the provisions of this Agreement violates or infringes such third
party’s rights; or (ii) any claims caused by the Licensor.

     C. Indemnification Procedures. The indemnified party shall provide the indemnifying party
with prompt written notice upon becoming aware of any claim subject to indemnification hereunder,
and shall provide reasonable cooperation to the indemnifying party in the defense of such claim;
provided that no failure or delay in providing the notice referred to above shall relieve the
indemnifying party of its indemnification obligations hereunder unless (and then only to the extent
that) the indemnified party is prejudiced thereby. So long as the indemnifying party is diligently
defending such claim, the indemnifying party shall have the right, through counsel of its choice,
to control the investigation and defense of such claim, and shall have sole authority to defend
and/or settle or compromise such claim at its expense and discretion; provided, however, that any
settlement of such a claim by the indemnifying party which does not include an unconditional
release of the indemnified party must be approved by the indemnified party (which approval shall
not to be unreasonably withheld or delayed). The indemnified party may participate in the defense
and/or settlement of any such claim at its own expense using counsel of its own choosing; provided,
however, that so long as the indemnifying is diligently defending such claim the indemnified party
shall not make or enter into any compromise or settlement of said claim without prior written
consent of the indemnifying party, which consent shall not be unreasonably withheld or delayed.

12. Arbitration.

     A. Agreement. Any dispute, controversy, claim or other matter in question between the
parties hereto arising out of or relating to this Agreement or any other document or instrument
executed by the parties hereto in connection with this Agreement contemplated in any of the
foregoing, including all issues of fact and law (for the purposes of this Section, the “Claim”),
shall be settled by arbitration in accordance with the Commercial Arbitration Rules of the American
Arbitration Association (the “Commercial Arbitration Rules”), except as otherwise expressly set
forth herein. Without limiting the generality of the foregoing, “Claims” shall also include any
dispute, controversy, claim or other matter in question arising out of or related to this Agreement
or any document or instrument executed by the parties hereto in connection herewith, it being the
purpose and intent hereof to evidence the agreement of all the parties hereto to submit all Claims
to arbitration. Notice of demand for arbitration shall be filed in writing with all parties to
this Agreement as to whom the Claim is alleged and with the American Arbitration Association (the
“AAA”). The arbitration proceeding shall be conducted by one disinterested

-10-

 

neutral arbitrator who shall be appointed from a panel in accordance with the Commercial
Arbitration Rules of the AAA; provided, however, that if a neutral arbitrator cannot be selected
and appointed by the parties to the dispute from the first list of names submitted by the AAA, then
the AAA shall submit to each party to the dispute a second list of names of persons chosen from the
panel, and if a neutral disinterested arbitrator cannot be appointed for any reason from said
second list, then the AAA shall then be deemed authorized and directed to and shall select and
appoint, on behalf of all parties to the dispute, one disinterested neutral arbitrator (but in no
event shall the AAA appoint an arbitrator whose name has previously been rejected by the parties to
the dispute). All persons submitted as prospective arbitrators by the AAA shall be persons having
substantial knowledge of substantive commercial laws and the general issues in question for
arbitration.

     B. Proceedings. The arbitrator shall conduct the arbitration proceeding in the State
of New Jersey if the Licensor initiates the dispute and in Memphis, Tennessee if Licensee initiates
the dispute, as provided hereinabove and in the Commercial Arbitration Rules. The arbitrator
rendering the judgment or award shall deliver a brief written opinion explaining such judgment or
award and the legal and factual reasons therefor. This agreement to arbitrate shall be
specifically enforceable under applicable law in any court having jurisdiction thereof. The award
rendered by the arbitrator shall be final, such judgment shall be entered upon it in accordance
with applicable law in a court hearing jurisdiction thereof and any such award or judgment shall be
subject to appeal in accordance with the same procedures and an the same legal basis as a final
judgment of the trial court in which such judgment is entered. The parties hereto agree to
expedite and cooperate in obtaining the entry of judgment with respect to such award. A demand for
arbitration shall be made within a reasonable time after the Claim or other matter in question has
arisen. In no event shall the demand for arbitration be made after the date when institution of
legal or equitable proceedings based on such Claim or the matter would be barred by applicable
statutes of limitation.

13. General.

A. Amendment, Modification and Waiver. The failure of either party to enforce its
rights or to require performance by the other party of any term or condition of this
Agreement shall not be construed as a waiver of such rights or of its right to require
future performance of that term or condition. Any amendment of modification of this
Agreement or any waiver of any breach of any term or condition of this Agreement must be in
a writing signed by both parties in order to be effective. Unless expressly provided
therein, a waiver of any breach of any term or condition of this Agreement shall not be
construed as a waiver of any continuing or subsequent breach of such term or condition, or a
waiver of any other right under this Agreement.

B. Governing Law. This Agreement and all matters arising directly and indirectly
from this Agreement (collectively “Agreement Matters”) shall be governed and interpreted
under the laws of the State of Delaware and the United States without regard to the
conflicts of laws provisions thereof. Subject to the provisions of Section 12 hereof, the
parties hereby irrevocably submit to the exclusive personal jurisdiction of the State and
Federal courts located in Delaware for the purpose of any suit, action, proceeding or
judgment which, directly or indirectly, arises out of any Agreement Matters; provided that a
party to this Agreement shall be entitled to enforce an order or judgment of a Delaware
court (or a federal appellate court of competent jurisdiction issuing the same on appeal
from a Delaware court) in any other court having jurisdiction over the other party hereto.
Each of the parties hereby irrevocably waives, to the fullest extent permitted by applicable
law, any objection that it may now or hereafter have to the laying of the venue of any such
proceeding brought in such a court and any claim that any such proceeding brought in such a
court has been brought in an inconvenient forum.

-11-

 

C. Headings. Headings and captions are for convenience of reference only and shall
not be deemed to interpret, supersede or modify any provisions of this Agreement.

D. Severability. In the event that any provision of this Agreement shall be
determined by a court of competent jurisdiction to be illegal or unenforceable, that
provision will be limited or eliminated to minimum extent necessary so that this Agreement
shall otherwise remain in full force and effect and enforceable.

E. Entire Agreement. Upon execution by both parties, this Agreement and the
attached Exhibits shall constitute the entire agreement between the parties with respect to
the subject matter hereof and supersede all discussions, negotiations, agreements and past
dealings, either oral or written, between or among the parties relating to the subject
matter hereof.

F. Nonexclusive Remedies. The rights and remedies of a party set forth herein are
not exclusive, the exercise thereof shall not constitute an election of remedies and the
aggrieved party shall in all events be entitled to seek whatever additional remedies may be
available in law or in equity.

G. Counterparts; Evidence of Signatures. For the convenience of the parties, any
number of counterparts of this License Agreement may be executed, and each such counterpart
shall be deemed to be an original instrument. Signatures transmitted by facsimile or
electronic mail (including, without limitation, electronic mailing of a so-called portable
document format or “pdf” of a scanned counterpart) shall be treated as and deemed to be
original signatures for all purposes, and will have the same binding effect as if they were
original, signed instruments delivered in person

H. Notices. Any notice, transmittal of documents, correspondence or other
communication between the parties to this Agreement required or permitted hereunder shall be
in writing, addressed to the party to whom sent and transmitted by certified mail, courier
or by facsimile with signed written original to follow by certified mail or courier. All
such notices in compliance with this provision shall be deemed received by the other party
on the next business day after transmission. For purposes of this Agreement, the addresses
of the parties are as follows until changed by written notice from the party desiring to
change its address to the other party.

	 	 	 

	If to Licensee:

	 	If to Licensor:
	 
	 	 
	KCI Medical Resources

	 	Wright Medical Technology, Inc.Zephyr House,
	Mary Street

	 	5677 Airline Road P.O. Box 709 GT
	 

	 	Arlington, TN 38002 Grand Cayman, Cayman
	Islands

	 	Attn: President Attn: Legal Department
	 

	 	Telephone: 901-867-4361 Facsimile: 901-867-4332
	 
	 	 
	With a copy to:
	 	 
	 
	 	 
	KCI USA, Inc.

	 	Wright Medical Technology, Inc.Vantage Way 

5677 Airline Road
	San Antonio, TX

	 	Arlington: TN 38002
	Attn: President

	 	Attn: General Counsel
	Telephone:

	 	Telephone: 901-867-4743
	Facsimile:

	 	Facsimile: 901-867-4398

-12-

 

     IN WITNESS WHEREOF, the parties hereto have each caused this Trademark License Agreement to be
executed by their authorized representatives as of the Effective Date.

	 	 	 	 	 	 	 	 	 
	Wright Medical Technology, Inc.	 	KCI Medical Resources	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Gary D. Henley
	 	By:
	 	/s/ Adriano Cito	 	 
	 

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Printed Name: Gary D. Henley

	 	Printed Name: Adriano Cito	 	 
	 
	 	 	 	 	 	 	 	 
	Title

	 	CEO
	 	Title
	 	Vice President, Finance	 	 

-13-

 

EXHIBIT A

	 	 	 
	Trademark	 	Application/Registration No.
	GRAFTJACKET
	 	2,765,465
	GRAFTJACKET XENO
	 	77192169
	GRAFTJACKET XPRESS	 	 

-14-

 

EXHIBIT B

Trademark Usage Guidelines

     1. For purposes of these Usage Guidelines, Licensed Marks are defined in accordance with the
License Agreement and shown on Exhibit A.

     2. Wherever possible, the Licensed Marks shall be used as adjectives. The Licensed Marks must
not be used as nouns, verbs, or any other form.

     3. The following are examples of correct and incorrect trademark use:

Never use a Licensed Mark as a noun:

Wrong: The GRAFTJACKETTM is used for human implantation

Correct: GRAFTJACKETTM biological tissue for human implantation

Never use a Licensed Mark in the possessive form:

Wrong: GRAFTJACKET’sTM biological tissue replacement function

Correct: GRAFTJACKETTM biological tissue’s replacement function

For avoidance of doubt, Licensee may compound a trademark with another term or use it to
coin another word or phrase.

Licensee is permitted to use the Licensed Marks in varying forms, formats, colors,
stylizations, and with designs or logos, provided that any such variant of the Licensed
Marks does not constitute a mutilation of any Licensed Mark.

4. Use the Generic Description in Association with the Trademark

The generic product name should ALWAYS be used with the trademark, which is the name applied
to the class of products or services identified by the trademark. For example, the owners
of the KLEENEX trademark always refer to it as KLEENEX brand facial tissues or KLEENEX
facial tissues, with facial tissues being the generic product name.

In printed matter of all types, particularly in advertising copy, the generic name should
accompany the first or most prominent use of each mark on each page, and should usually
appear in all lower case letters. The generic name need not be used every time the
trademark appears, but it should be used often enough to make it obvious that the trademark
is not the generic name.

The following are rules of thumb to follow for using the generic product name when placing a
trademark on a product or using the trademark in any type of print or electronic materials:

a) On the product or in connection with the services. When a trademark is applied directly
to a product, or to print or electronic materials advertising a service, the generic name
should always be placed after the trademark. In certain situations, such as if the
appearance of the product conveys its own generic description, the generic name need not be
placed on the product.

-15-

 

For example, use of the trademark “Cadillac” on a car does not require the generic product
name “car” after the trademark, as it is clear the mark is being used on a car.

b) In print and electronic materials. Here, it is very important to use the generic product
or service name with a trademark, since using only the trademark will not clearly convey the
generic product or service name. The generic product or service name should accompany the
first or most prominent use of each mark on each print or electronic page, and should
usually appear in all lower case letters. The generic name need not be used every time the
trademark appears, but it should be used often enough to make it obvious that the trademark
is not the generic name.

5. Proper Notice of Trademarks in the U.S.

Whether a trademark has been registered or not, proper marking is essential to protect
valuable rights in the marks. Without such notice, some of these valuable rights may not be
enforceable.

     Federally Registered Trademarks®

     One of the following forms of notice should be used if a trademark is federally registered:

	•	 	The statutory symbol ® placed on the “shoulder” or the “heel” of the trademark, as in:

	 	 	 

	GRAFTJACKET®
	 	GRAFTJACKET®

     Alternatively, an asterisk or footnote placed on the shoulder of the trademark with a footnote
reading “Registered in the U.S. Patent and Trademark Office” or “Reg. U.S. Pat. & Tm. Off.”

NOTE: NEVER USE THE SYMBOL ® WITH AN UNREGISTERED TRADEMARK OR WITH A TRADEMARK WHERE
FEDERAL REGISTRATION HAS BEEN REQUESTED BUT NOT YET GRANTED.

	•	 	A notation that the trademark is owned by Wright Medical Technology, Inc., as in “GRAFTJACKET is
a Wright Medical Technology, Inc. Trademark” or “The GRAFTJACKET trademark is a registered
trademark of Wright Medical Technology, Inc.”

     Place the notation on the page where the trademark appears or at the front or back of a
brochure.

Common Law Mark or Mark Pending at the Trademark Office

                         TM      or       SM

     If a trademark is being used and has not been federally registered, one of the following
forms of notice should be used:

-16-

 

	•	 	The initials “TM” or “SM” on the shoulder or heel of each mark. The “TM” symbol is used to
identify tangible goods, where as the “SM” symbol is used to identify intangible services.

	•	 	A notation that Wright Medical Technology, Inc. claims trademark rights, as in “The
GRAFTJACKET ZENO trademark is a trademark of Wright Medical Technology, Inc.” or “The
GRAFTJACKET XPRESS trademark is a trademark of Wright Medical Technology, Inc.,” etc. Place
this notation in the same location as for registered trademarks.

-17-

 

EXHIBIT C

Product SKUs

	 	 	 	 	 
	LifeCell SKU	 	Description	 	WMT SKU
	663002	 	GRAFTJACKET XPRESS, 2CC	 	86GL2000
	702032	 	GRAFTJACKET, Ulcer Repair, 4x8 cm,
..38-1.02 (mm)	 	86TM4X08
	712016	 	GRAFTJACKET, Ulcer Repair, 4x4 cm,
..38-.76 (mm)	 	86TM4X4S

 

			
	 	 	 

-18-

 

EXHIBIT D

Transition Plan

Licensor shall use commercially reasonable efforts to complete the following tasks by the dates set
forth below:

By January 31, 2011

Transfer to KCI priority marketing, training, reimbursement, and other transition materials of the
following types:

A. Marketing materials;

B. Available primary and secondary market research conducted or analyzed;

C. Promotional and scientific marketing materials including, but not limited to, the transfer of
complete files from any promotion agency for Licensor’s assets, copy of the pivotal DFU study
article from the Intl Wound Journal, spreadsheet with raw data from the pivotal DFU study and
report with graphs and analyses that were performed in preparation of the Intl Wound Journal
manuscript, all web assets and materials, and all KOL contacts;

D. Electronic and print training materials including, but not limited to, training presentation,
documents hosted by a third party, application videos and similar materials;

E. Summary institutional and product performance tracking data including, but not limited to, sales
force targeting information and ICD-9 information; (i.e. performance reports of overall wound line,
coverage vs. non-coverage areas, etc.)

F. Information relating to the method or manner in which the Licensed Goods are distributed by
Licensor; and

G. A comprehensive overview of Licensor’s reimbursement programs for their products branded with
the Licensed Marks in the Wound Care Field, including information regarding the coverage of such
products under Medicare. All non-privileged materials associated with reimbursement programs to be
transferred.

H. Initiate transfer of branding assets and website assets to KCI, including proper introduction
and directive to relevant vendors to transition assets.

I. WMT to cease all medical education and promotional efforts at medical meetings and cease
promotion in medical journals related to wound applications of GraftJacket products.

By March 15, 2011

Introduce KCI to current KOLs for GraftJacket wound applications.

Complete transfer of all items, in addition to priority materials, related to topics included in A
— I above.

Provide to KCI a complete customer list, excluding the Top 150 WMT Accounts, of past and current
customers of products branded with the Licensed Marks in the Wound Care Field, together with
contact names where available, facility locations, purchase history, average selling price (current
and in the past) at which Licensor or its distributors sell Products to various facilities, and
other customer data associated with such customers that are maintained by Licensor in the normal
course of business.

Develop & send formal announcement letter from WMT to all accounts, excluding the Top 150 WMT
Accounts, providing introduction of KCI as new sales channel for all wound sales of GraftJacket
product and introducing KCI sales reps to relevant personnel (e.g., Surgeons, purchasing
department, etc) at Wright wound care accounts. KCI to review proposed letters to accounts and
receive copies of the letters sent to WMT accounts to assist KCI representatives in communicating
change to WMT accounts.

Formal announcement letter detailing KCI — WMT partnership to be sent to all accounts, excluding
Top 150 WMT Accounts, by or on March 15, 2011.

-19-

 

By April 30, 2011

Provide to KCI a complete customer list of the Top 150 WMT Accounts, of past and current customers
of products branded with the Licensed Marks in the Wound Care Field, together with contact names
where available, facility locations, purchase history, average selling price (current and in the
past) at which Licensor or its distributors sell Products to various facilities, and other customer
data associated with such customers that are maintained by Licensor in the normal course of
business.

Develop & send formal announcement letter from WMT to the Top 150 WMT Accounts, providing
introduction of KCI as new sales channel for all wound sales of GraftJacket product and introducing
KCI sales reps to relevant personnel (e.g., Surgeons, purchasing department, etc) at Wright wound
care accounts, by or on April 30, 2011. KCI to review proposed letters to accounts and receive
copies of the letters sent to WMT accounts to assist KCI representatives in communicating change to
WMT accounts.

By June 30, 2011

Remove all information relating to GraftJacket for wound applications from its website.

Through remainder of Transition Period (December 31, 2011)

Provide ongoing sales training support, reimbursement and product MAC coverage support during the
Transition Period. KCI shall provide reasonable notice when support is needed.

For the duration of the Agreement, WMT and KCI to jointly coordinate on reporting ASP details for
GraftJacket.

Exceptions

Notwithstanding the foregoing, Licensor shall not be required to deliver to KCI or provide KCI
access to any correspondence with its legal counsel or any other documents or materials provided to
or by its legal counsel which Licensor reasonably believes is subject to or qualifies for the
attorney client privilege.

-20-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00183-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00183-of-00352.parquet"}]]